DOI: 10.1002/asia.200600228

Enantioselective Synthesis of 3,4-Dihydropyran-2-ones by Domino Michael Addition and Lactonization with New Asymmetric Organocatalysts: Cinchona-Alkaloid-Derived Chiral Quaternary Ammonium Phenoxides

Takashi Tozawa, [a, b] Hitoshi Nagao, [a] Yoshinobu Yamane, [a] and Teruaki Mukaiyama*[a, c]

Abstract: Chiral quaternary ammonium phenoxides were readily prepared from commercially available cinchona alkaloids and proved to be useful new asymmetric organocatalysts. Among various chiral quaternary ammonium phenoxides, a cinchonidine-derived catalyst that bears both a sterically hindered *N*1-9-anthracenylmethyl group and a strongly electron withdrawing 9-

O-3,5-bis(trifluoromethyl)benzyl group were found to be highly effective for the Michael addition of ketene silyl acetals (derived from phenyl carboxylates) and α , β -unsaturated ketones

Keywords: alkaloids • dihydropyranones • domino reactions • Michael addition • organocatalysis

followed by lactonization. Optically active 3,4-dihydropyran-2-one derivatives were obtained in high yields with excellent control of enantio- and diastereoselectivity. This catalyst can be handled in air and stored at room temperature in a sealed bottle without decomposition for at least one month.

Introduction

Six-membered oxygen-containing heterocycles such as dihydropyrans and dihydropyranones are widely recognized as useful building blocks for the synthesis of various biologically active compounds. 2,3-Dihydropyran-4-one derivatives are characteristic among them, for which hetero-Diels–Alder reactions of 1-alkoxy-3-trialkylsilyloxy-1,3-butadienes (Danishefsky dienes) with aldehydes are the best known method for the construction of the 2,3-dihydropyran-4-one skeleton. Effective chiral metal-based Lewis acids and hydrogen-bonding catalysts for these hetero-Diels–Alder reactions have been developed and applied to the total synthesis of various natural products.^[1] On the other hand, 3,4-dihydropyran-2-one derivatives are useful synthetic intermediates for the preparation of 2-pyranones, γ-lactones, cyclic en-

ods for the synthesis of 3,4-dihydropyran-2-ones. Among the few, an intramolecular cyclization through Michael addition is considered to be one of the most synthetically efficient and powerful strategies because it provides a wide variety of 3,4,6-trisubstituted-3,4-dihydropyran-2-ones in a one-pot preparation.^[3] In 1997, Kobayashi et al. reported the first example of a facile one-pot synthesis of 3,4-dihydropyran-2ones through a trityl salt catalyzed Michael reaction of silyl enol ethers derived from thioesters with α,β-unsaturated ketones and subsequent intramolecular cyclization of the resulting Michael adducts.[3b] Although this method provided the desired 3,4-dihydropyran-2-ones in excellent yields with high diastereoselectivity, excess toxic mercuric trifluoroacetate, Hg(OCOCF₃)₂, was required for the cyclization of the Michael adducts. In 2002, Katritzky et al. demonstrated that the reactions of lithium enolates of N-acylbenzotriazoles with α,β -unsaturated ketones afforded 3-alkyl 4,6-diaryl 3,4dihydropyran-2-one derivatives in good yields.[3c] However, the scope of this method with regard to the preparation of substituted 3,4-dihydropyran-2-ones was limited to derivatives with unbranched alkyl substituents at the 3-position. Therefore, it is important to develop an efficient method for the synthesis of 3,4-dihydropyran-2-ones based on a broader concept. Recently, it was reported from our laboratory that

a convenient one-pot preparation of 3,4-dihydropyran-2-

ones was achieved by Michael addition and successive lacto-

nization between various α,β-unsaturated ketones and

amines, etc., [2] although there are not many effective meth-

- [a] Dr. T. Tozawa, H. Nagao, Y. Yamane, Prof. Dr. T. Mukaiyama The Kitasato Institute, Center for Basic Research 6-15-5 (TCI) Toshima, Kita-ku, Tokyo 114-0003 (Japan) Fax: (+81)3-3911-3482 E-mail: mukaiyam@abeam.ocn.ne.jp
- [b] Dr. T. Tozawa Mitsubishi Pharma Corporation 1000 Kamoshida-cho, Aoba-ku, Yokohama 227-0033 (Japan)
- [c] Prof. Dr. T. Mukaiyama Kitasato Institute for Life Science Kitasato University 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641 (Japan)

ketene silyl acetals derived from phenyl carboxylates in the presence of a catalytic amount of tetrabutylammonium phenoxide.^[4] A catalytic cycle for the phenoxide-ion-catalyzed domino Michael addition and lactonization is illustrated in Scheme 1. In the presence of tetrabutylammonium

OSiMe₃

$$R_4N$$
OPh
 R_2
 R_4N
OPh
 R_4N
OPh

Scheme 1. Phenoxide-ion-catalyzed domino Michael addition and lactonization.

phenoxide **1** (R=nBu), ketene silyl acetals **3** are activated by nucleophilic attack of the phenoxide ion on the silicon center to react with α,β -unsaturated ketones **2** to afford Michael-adduct intermediates **4** and the trimethylsilyl ether of phenol. The ester carbonyl group in **4** undergoes intramolecular attack by the enolate intermediate formed in situ to form the corresponding 3,4-dihydropyran-2-ones **5** along with elimination of the phenoxide ion. In this catalytic system, the phenoxy group contained in the ketene silyl acetals works as an effective leaving group to facilitate intramolecular cyclization of the Michael-adduct intermediate.

To demonstrate further the synthetic utility and versatility of the phenoxide-ion-catalyzed domino Michael addition and lactonization, it was next planned to use chiral quaternary ammonium phenoxides in an asymmetric synthesis of 3,4-dihydropyran-2-one derivatives. Despite the fact that chiral quaternary ammonium halides have been widely em-

Abstract in Japanese:

入手容易なシンコナアルカロイドから導かれる 4級アンモニウムフェノキシドは新しい有用な不斉有機分子触媒である。今回、シンコニジンのN1位に立体障害の大きい 9 ーアントラセニル基を、また、C 9 位の酸素原子に電子吸引性の強い 3 , 5 ービストリフルオロメチルベンジル基を導入した 4 級アンモニウムフェノキシドをルイス塩基触媒として用い、 α , β 一不飽和ケトンと各種ケイ素エノラートを反応させると、マイケル付加および連続するラクトン化反応が速やかに進行し、高いジアステレオかつエナンチオ選択性をもって、3 , 4 ージヒドロー 2 ーピラノンが生成することを明らかにした。この触媒は空気中でも取り扱いができ、また 1 か月以上、室温において分解せずに保存することができる。

ployed as catalysts in synthetically useful stereoselective carbon–carbon bond-forming reactions, and many excellent catalytic asymmetric reactions have been developed in accordance with the advancement of newer effective catalysts,^[5] there is no successful example of chiral quaternary

ammonium phenoxides asymmetric organocatalysts in synthetic reactions.[6] Herein we describe in detail our studies on the use of cinchona-alkaloid-derived chiral quaternary ammonium phenoxides 1 in catalytic domino Michael addition and lactonization reactions between ketene silvl acetals derived from phenyl carboxylates and α,β-unsaturated ketones form optically active 3,4-dihydropyran-2-one derivatives.

Results and Discussion

Synthesis of Cinchona-Alkaloid-Derived Chiral Quaternary Ammonium Phenoxides

Cinchona alkaloids have often been employed in asymmetric reactions, and various catalysts derived from cinchonidine and cinchonine have been developed extensively in chiral phase-transfer catalysis because these alkaloids are in-

International Advisory Board Member



Teruaki Mukaiyama was born in Nagano, Japan, in 1927. He obtained is BSc from the Tokyo Institute of Technology and his PhD from the Univ. of Tokyo. He currently runs his own basic research laboratory at the Kitasato Institute. He is Prof. Emeritus at the Univ. of Tokyo, the Tokyo Institute of Technology, and the Science Univ. of Tokyo. He is a member of the Japan Academy, and a foreign member of the Polish, French, and American Academies. He has published over 900 scientific papers and has been awarded a number of prizes for his achievements in organic synthesis.

"As with her sister journal, Chemistry—A European Journal, Chemistry—An Asian Journal is sure to become one of the leading journals of the chemical community worldwide"

expensive, readily available in both pseudoenantiomeric forms, and can easily be converted into effective phasetransfer catalysts.^[5] Therefore, cinchonidine was chosen as a chiral source and cinchonidine-derived chiral quaternary ammonium phenoxides 1 were synthesized in three or four steps as shown in Scheme 2. Cinchonidine-derived chiral quaternary ammonium halides 6 and 7 were first prepared according to the procedure reported by Corey et al. [6] Once formed, 6 and 7 were transformed into the corresponding quaternary ammonium hydroxides in an anion-exchange reaction by using amberlyst A-26 (OH⁻) in methanol.^[7] The resulting ammonium hydroxide intermediates were then treated with phenol (1.0-2.0 equiv). The resultant mixture was co-evaporated with benzene three times, and crystallization of the residue from diethyl ether afforded pale-yellow solids, which were collected by filtration and dried under reduced pressure to give N,O-diarylmethylated cinchonidinium phenoxides 1a-k and N-arylmethylated cinchonidinium

phenoxides 1m-q, which bear a free hydroxy group. It was also confirmed that cinchonine-derived chiral quaternary ammonium phenoxides were similarly prepared from cinchonine as a chiral starting material. Thus, a synthetic route to cinchona-alkaloid-derived chiral quaternary ammonium phenoxides, new asymmetric organocatalysts, was established. Notably, most of the compounds can be handled in air and stored at room temperature in a sealed bottle without decomposition for at least one month.

After detailed analysis of the cinchona-alkaloid-derived chiral quaternary ammonium phenoxides, some of these compounds with electron-withdrawing substituents were found to consist of quaternary ammonium phenoxide–phenol complexes $[R_4N^+\cdot C_6H_5O^-\cdot C_6H_5OH]^{[8]}$ by 1H NMR spectroscopic and elemental analysis (see Experimental Section). For example, the 1H NMR spectrum of cinchonidine-derived chiral quaternary ammonium salt 1k (Ar $^1=9$ -anthracenyl, $R^5=3,5$ -bis(trifluoromethyl)benzyl) is shown in

Scheme 2. Synthesis of cinchonidine-derived chiral quaternary ammonium phenoxides.




Figure 1. ¹H NMR spectrum of **1k** in CD₃OD.

Figure 1, and the signals for the aromatic protons (10 H) of both the phenoxide and phenol groups appear at approximately δ =6.5–7.0 ppm.

Asymmetric Synthesis of 3,4-Dihydropyran-2-ones by N,O-Diarylmethylated Cinchonidinium Phenoxide Catalyzed Domino Michael Addition and Lactonization^[9]

For initial evaluation of the catalytic efficiency of cinchonidine-derived chiral quaternary ammonium phenoxides, reactions of chalcone 2a with ketene silyl acetal 3a derived from phenyl isobutyrate were tried in THF at $-78\,^{\circ}$ C for 1 h in the presence of N,O-diarylmethylated cinchonidinium phenoxides 1a–f (10 mol%), and the effects of the arylmethyl substituents at N1 (Ar¹) were examined (Table 1).

Table 1. Effects of N1-arylmethyl substituents (Ar¹) of N,O-diarylmethylated cinchonidinium phenoxides.

Entry	Catalyst 1 (Ar1)	Yield [%] ^[a]	ee [%] ^[b]
1	a (Ph)	96	2
2	b (4-CF ₃ C ₆ H ₄)	99	4
3	$\mathbf{c} (3,5-(tBu)_2C_6H_3)$	96	12
4	d (1-naphthyl)	93	16
5	e (2-naphthyl)	96	27
6	f (9-anthracenyl)	94	78
7 ^[c,d]	f (9-anthracenyl)	12	76

[a] Yield of isolated product. [b] The enantiomeric excess of (+)-5a was determined by HPLC analysis using a chiral column (DAICEL Chiralcel OD-H) with hexane/2-propanol as solvent. [c] Catalyst used: 5 mol%. [d] The reaction was carried out over 6 h.

When the catalyst **1a**, which bears a simple phenyl group, was used, Michael addition and successive lactonization proceeded smoothly to afford the desired 3,4-dihydropyran-2-one (+)-**5a** in 96 % yield, but the enantioselectivity of the product was very poor (only 2 % *ee*) (Table 1, entry 1). The introduction of bulky substituents such as a 3,5-di-*tert*-butylphenyl group (**1c**), a 1-naphthyl group (**1d**), or a 2-naphthyl group (**1e**) as Ar¹ enhanced the enantioselectivity slightly (Table 1, entries 3–5). When catalyst **1f**, which bears a sterically more-hindered 9-anthracenylmethyl group [6,10] at the quinuclidine nitrogen atom, was employed, the enantiomeric excess of (+)-**5a** increased dramatically to up to 78 % (Table 1, entry 6).

To improve the enantioselectivity of this asymmetric domino reaction further, the effects of the 9-O-arylmethyl substituents (Ar²) of N,O-diarylmethylated catalysts were

Table 2. Effects of 9-O-arylmethyl substituents (Ar 2) of N,O-diarylmethylated catalysts.

Entry	Catalyst 1 (Ar ²)	Yield [%] ^[a]	ee [%] ^[b]
1	g (4-MeC ₆ H ₄)	89	77
2	\mathbf{h} (4-MeOC ₆ H ₄)	87	64
3	i (4-ClC ₆ H ₄)	95	81
4	$j (4-NO_2C_6H_4)$	96	88
5	$\mathbf{k} (3,5-(CF_3)_2C_6H_3)$	98	89
6 ^[c]	$\mathbf{k} (3.5 - (CF_3)_2 C_6 H_3$	98	90
7	$I(3,5-(CF_3)_2C_6H_3)$	96	85 ^[d]

[a] Yield of isolated product. [b] The enantiomeric excess of (+)-5a was determined by HPLC analysis using a chiral column (DAICEL Chiralcel OD-H) with hexane/2-propanol as solvent. [c] Catalyst used: 5 mol%. [d] The opposite enantiomer (-)-5a was obtained.

examined next (Table 2). The use of catalysts with electrondonating substituents such as a 4-methylphenyl group (1g) or a 4-methoxyphenyl group (1h) caused a slight decrease in the enantioselectivity of (+)-5a (Table 2, entries 1 and 2). On the other hand, catalysts with electron-withdrawing substituents such as a 4-chlorophenyl group (1i) or a 4-nitrophenyl group (1j) led to a slight increase in the enantioselectivity (Table 2, entries 3 and 4). Further structural modification of Ar² by introducing a strongly electron-withdrawing 3,5-bis(trifluoromethyl)phenyl group (1k) improved not only the enantioselectivity but also the catalytic activity, and (+)-5a was obtained in 98% yield with 90% ee, even when the amount of the catalyst was decreased to 5 mol% (Table 2, entry 6). It was also found that the opposite enantiomer of the 3,4-dihydropyran-2-one (-)-5a was accessible if the pseudoenantiomeric cinchonine-derived catalyst 11 was used (Table 2, entry 7).

The absolute configuration of 3,4-dihydropyran-2-one (+)-5a was determined to be *R* by X-ray crystallographic analysis after conversion into the corresponding carboxamide 10 as shown in Scheme 3. The reductive ring-opening reaction of (+)-5a to carboxylic acid 9 was accomplished by catalytic hydrogenation with Pd/C under hydrogen, followed by amidation of 9 with 4-bromoaniline and recrystallization from EtOAc/hexane to afford carboxamide 10 as a crystalline compound, which was clearly identified by X-ray crystallographic analysis.^[11]

The reactions of various α,β -unsaturated ketones 2 with ketene silyl acetal 3a were tried in THF at -78 °C by using the most efficient cinchonidine-derived catalyst 1k, which bears both the sterically hindered 9-anthracenylmethyl

Scheme 3. Conversion of (+)-5a into carboxamide 10 and determination of the absolution configuration. ORTEP diagram drawn at the 50% probability level.

group and the strongly electron withdrawing O-3,5-bis(trifluoromethyl)benzyl group (Table 3). In most cases, the reactions proceeded smoothly to provide the corresponding 3,4-dihydropyran-2-ones 5 in high yields with high enantiomeric excesses. It was found that various types of α , β -unsaturated ketones with electron-withdrawing or -donating substituents on R^1 or R^2 were successfully employed in this procedure.

Asymmetric Domino Michael Addition and Lactonization by Using Cinchonidine-Derived Chiral Quaternary Ammonium Phenoxides That Bear a Hydroxy Group

To investigate further structural modification of the catalyst, N-arylmethylated cinchonidinium phenoxides with a hydroxy group instead of the above-mentioned N,O-diarylmethylated cinchonidinium phenoxides were also studied. The reactions of chalcone 2a with ketene silyl acetal 3a derived from phenyl isobutyrate were carried out in THF at −78 °C in the presence of N-arylmethylated cinchonidinium phenoxides 1 m-q (10 mol%), and the effects of the N1-arylmethyl substituents (Ar1) were examined (Table 4). When the cinchonidine-derived catalyst 1m with a simple benzyl substituent at the quinuclidine nitrogen atom was used, the reaction proceeded smoothly to afford the desired 3,4-dihydropyran-2-one 5a in 97% yield with 24% ee (Table 4, entry 2). Interestingly, the absolute configuration of the product was proved to be S, which was the reversal of the case when using N,O-diarylmethylated cinchonidinium phenoxides such as catalyst 1k under the same reaction conditions. Structural modification of Ar¹ by introducing bulky and/or electron-withdrawing substituents such as a 9-anthracenyl group (1n), a 3,5-bis(trifluoromethyl)phenyl group (10), or a 3,5-di-tert-butylphenyl group (1p) as Ar^1 enhanced the enantioselectivity (Table 4, entries 3–5). Finally, cinchonidine-derived catalyst 1q, which bears both a free hydroxy group and a 3,5-bis[3,5-bis(trifluoromethyl)phenyl]benzyl group, was found to be the most effective, and (S)-

(-)-5a was obtained in 97% yield 87% ee, even when the amount of the catalyst was de-5 mol % to (Table 4. entry 7). These observations indicated that a hydroxy function contained in the cinchonidine-derived catalyst plays an important role in controlling the absolute stereochemistry of the newly created stereogenic carbon center in this asymmetric domino reaction. Although the detailed mechanism has not vet been clarified, it is conceivable that hydrogen-bonding interactions between the hydroxy group of the catalyst and the carbonyl group of the substrate is involved in controlling the addition of the nucleophile in the transition state.^[12]

Table 3. Reactions of various α,β -unsaturated ketones 2 with ketene silyl acetal 3a in the presence of cinchonidine-derived catalyst 1k.

Entry	α,β-Unsaturated ketone			Product	Yield	ee
	2	\mathbb{R}^1	\mathbb{R}^2		$[\%]^{[a]}$	$[\%]^{[b]}$
1	a	Ph	Ph	(R)-5a	98	90
2	b	Ph	$4-FC_6H_4$	5 b	98	84
3	c	$4-FC_6H_4$	Ph	5 c	94	82
4	d	Ph	$4-MeOC_6H_4$	5 d	98	96
5	e	4-MeOC ₆ H ₄	Ph	5 e	98	95
6	f	$4-MeOC_6H_4$	4 -BrC $_6$ H $_4$	5 f	95	88
7	g	$4-BrC_6H_4$	$4-MeOC_6H_4$	5 g	98	89
8	h	Ph	Me	5 h	86	95
9	i	Ph	iPr	5i	98	93

[a] Yield of isolated product. [b] The enantiomeric excess of (+)-5 was determined by HPLC analysis using a chiral column (DAICEL Chiralcel OD-H or Chiralpak AD-H) with hexane/2-propanol as solvent.

Enantio- and Diastereoselective Synthesis of 3,4-Dihydropyran-2-ones by N,O-Diarylmethylated Cinchonidinium Phenoxide Catalyzed Domino Michael Addition and Lactonization^[13]

The diastereoselectivity of the two newly created adjacent carbon centers was studied in detail to explore the potential of this asymmetric domino reaction further. In the presence of 5 mol% of cinchonidine-derived catalyst 1k, which bears

Table 4. Asymmetric domino Michael addition and lactonization by using cinchonidine-derived chiral quaternary ammonium phenoxides that bear a hydroxy group.

Entry	Catalyst 1 (Ar ¹)	Yield [%] ^[a]	ee [%] ^[b] (config.)
1	k	98	90 (R) ^[c]
2	m (Ph)	97	24 (S)
3	n (9-anthracenyl)	32	43 (S)
4	$o(3,5-(CF_3)_2C_6H_3)$	96	60 (S)
5	$\mathbf{p} (3.5 - (tBu)_2 C_6 H_3)$	92	83 (S)
6	$\mathbf{q} (3.5-(3.5-(CF_3)_2C_6H_3)_2C_6H_3)$	96	87 (S)
7	\mathbf{q} (3,5-(3,5-(CF ₃) ₂ C ₆ H ₃) ₂ C ₆ H ₃)	97	87 (S) ^[c]

[a] Yield of isolated product. [b] The enantiomeric excess of **5a** was determined by HPLC analysis using a chiral column (DAICEL Chiralcel OD-H) with hexane/2-propanol as a solvent. [c] Catalyst used: 5 mol %.

both the N1-9-anthracenylmethyl and the 9-O-3,5-bis(trifluoromethyl)benzyl groups, reactions of chalcone 2a with various (E)-ketene silvl acetals **3b-f** derived from phenyl carboxylates were tried in THF at -78°C, and the stereochemical behavior of the alkyl substituents R³ of the ketene silyl acetals 3 was examined (Table 5). When ketene silyl acetal **3b** (R^3 =Me) derived from phenyl propionate was used, the domino reaction proceeded smoothly to afford the corresponding 3,4-dihydropyran-2-one 5j in 91% yield with high trans selectivity (trans/cis = 92:8), although the enantioselectivity of the major trans isomer turned out to be poor (25 % ee) (Table 5, entry 1). Structural assignment of the diastereomeric 3,4-dihydropyran-2-ones was based on the ¹H NMR chemical shift of the characteristic vinyl proton, which resonated at a lower magnetic field in the cis isomer than in the trans isomer. [4b] Next, it was observed that the use of ketene silyl acetal 3c ($R^3 = Et$) derived from phenyl *n*-butyrate enhanced both diastereo- and enantioselectivity, and the desired product 5k was obtained quantitatively with excellent trans selectivity (trans/cis=99:1) and 67% ee (trans isomer) (Table 5, entry 2). Significantly, the reactions that used sterically more-hindered ketene silyl acetals 3e $(R^3 = iPr)$ and 3f $(R^3 = tBu)$ produced the corresponding 3,4-dihydropyran-2-ones 5m and 5n in excellent yields with almost complete stereochemical control (trans/cis > 99:1, 96% ee) (Table 5, entries 4 and 5). It was consequently revealed that the alkyl substituents R³ in the ketene silyl acetals play an important role in controlling both the diastereoand enantioselectivity of this asymmetric reaction, and therefore stereoselectivity improved as the bulk of R³ in-

To improve the stereoselectivity of the above-mentioned reactions further, particularly in the case of ketene silyl ace-

Table 5. Reactions of chalcone 2a with various ketene silyl acetals 3 in the presence of cinchonidine-derived catalyst 1k.

Entry	3 (R ³) ^[a]	Product	Yield [%] ^[b]	trans/cis ^[c]	ee [%] ^[d]
1	b (Me)	5j	91	92:8	25 (75 ^[e])
2	c (Et)	5 k	99	99:1	67
3	d (<i>i</i> Bu)	51	96	99:1	76
4	e (<i>i</i> Pr)	5 m	99	>99:1	96
$5^{[f,g]}$	$\mathbf{f}(t\mathbf{B}\mathbf{u})$	5n	96	>99:1	96

[a] E/Z > 95:5. [b] Yield of isolated product. [c] The diastereomeric ratio was determined by ¹H NMR spectroscopic analysis. [d] The enantiomeric excess of the major *trans-5* isomer was determined by HPLC analysis using a chiral column (DAICEL Chiralpak AD-H) with hexane/2-propanol (50:1 v/v) as solvent. [e] Enantiomeric excess of the minor cis-5j isomer. [f] Catalyst used: 10 mol%. [g] The reaction was carried out at -78° C for 0.5 h, and the reaction mixture was then gradually warmed to room temperature.

tals with relatively small alkyl substituents R³, the effects of the aryl substituents Ar³ in the ketene silvl acetals were also examined (Table 6). Introduction of sterically hindered aryl substituents such as a 1-naphthyl group (3h) and a 2-isopropylphenyl group (3i) instead of a simple phenyl group (3c) enhanced the enantioselectivity, and trans-5k was obtained in 95% yield with 76% ee when ketene silyl acetal 3i (R^3 = Et, $Ar^3 = 2-iPrC_6H_4$) was used (Table 6, entry 4). Next, the effect of other solvents was examined by taking the reaction of 2a with ketene silyl acetal 3i. When the reaction was tried in toluene, the desired product was not obtained owing to the poor solubility of the catalyst (Table 6, entry 5). Among the solvents examined, a mixture of toluene and CH_2Cl_2 (1:1 v/v) gave the best result, and the enantiomeric excess of trans-5k increased to up to 84% (Table 6, entry 7). Taking the above results into consideration, it was also noted that the use of ketene silyl acetals **3b** ($R^3 = Me$, $Ar^3 =$ $2-iPrC_6H_4$) and **3d** (R³=iBu, Ar³= $2-iPrC_6H_4$) improved the stereoselectivity to give the corresponding 3,4-dihydropyran-2-ones 5j and 5l with excellent trans selectivity and appreciable enantioselectivity (Table 6, entries 9 and 11).

The reactions of ketene silyl acetals **3e** ($R^3 = iPr$, $Ar^3 = Ph$) and **3i** ($R^3 = Et$, $Ar^3 = 2 - iPrC_6H_4$) with various α, β -unsaturated ketones **2** were then tried in the presence of cinchonidine-derived catalyst **1k** (5 mol %) in THF or in toluene/ CH_2Cl_2 (1:1 v/v) at $-78\,^{\circ}C$ (Table 7). In most cases, the reactions proceeded smoothly to provide the corresponding 3,4-dihydropyran-2-ones **5** in high yields with almost complete *trans* selectivity and high to excellent enantioselectivity. The relative and absolute configurations at the two newly created adjacent carbon centers of compound **5s** were clearly identified by X-ray crystallographic analysis (Figure 2). [14]

Table 6. Effects of aryl substituents Ar³ in ketene silvl acetals 3.

Entry	3 ^[a] Ar ³	\mathbb{R}^3	Solvent	Yield [%] ^[b]	trans/ cis ^[c]	ee [%] ^[d]
1	c (Ph)		THF	99	99:1	67
2	g (2-naphthyl)		THF	93	98:2	55
3	h (1-naphthyl)		THF	84	>99:1	70
4	i (2- <i>i</i> PrC ₆ H ₄)	г.	THF	95	>99:1	76
5	i (2- <i>i</i> PrC ₆ H ₄)	Et	toluene	trace	_	_
6	i (2- <i>i</i> PrC ₆ H ₄)		CH_2Cl_2	95	98:2	77
7	i (2- <i>i</i> PrC ₆ H ₄)		toluene/ CH ₂ Cl ₂ ^[e]	99	>99:1	84
8	b (Ph)		THF	91	92:8	25
9	j (2- <i>i</i> PrC ₆ H ₄)	Me	toluene/ CH ₂ Cl ₂ ^[e]	93	98:2	57
10	d (Ph)		THF	96	99:1	76
11	$\mathbf{k} (2-i\mathrm{PrC}_6\mathrm{H}_4)$	<i>i</i> Bu	toluene/ CH ₂ Cl ₂ ^[e]	99	>99:1	88

[a] E/Z > 95:5. [b] Yield of isolated product. [c] The diastereomeric ratio was determined by ¹H NMR spectroscopic analysis. [d] The enantiomeric excess of the major *trans-5* isomer was determined by HPLC analysis using a chiral column (DAICEL Chiralpak AD-H) with hexane/2-propanol (50:1 v/v) as solvent. [e] 1:1 v/v.

Figure 2. ORTER drawing of compound $\mathbf{5s}$ (ellipsoids drawn at the 50% probability level).

asymmetric domino Michael addition and lactonization between various ketene silyl acetals derived from phenyl carboxylates and α,β -unsaturated ketones in the presence of a catalytic amount of cinchona-alkaloid-derived chiral quaternary ammonium phenoxides, novel types of air-stable and storable organocatalysts. Furthermore, unique relationships between the structure of the catalyst and the absolute stereochemistry in this asymmetric domino reaction were described. Further studies on the use of chiral quaternary ammonium phenoxides in other catalytic asymmetric reactions, particularly by using various organosilicon reagents, are now in progress.

Table 7. Enantio- and diastereoselective synthesis of 3,4-dihydropyran-2-ones by using cinchonidine-derived catalyst 1k.

Entry	R ¹	R ²	\mathbb{R}^3	Solvent	Product	Yield [%] ^[a] (trans/cis) ^[b]	ee [%] ^[c]
1	Ph	4-FC ₆ H ₄			5 o	98 (>99:1)	95
2	$4-FC_6H_4$	Ph			5 p	92 (>99:1)	94
3	Ph	$4-MeOC_6H_4$	iPr	TELLE	5q	93 (>99:1)	94
4	$4-MeOC_6H_4$	Ph	(3e)	THF	5r	94 (>99:1)	97
5	$4-MeOC_6H_4$	4-BrC6H4			5 s	98 (>99:1)	95
6	4-BrC ₆ H ₄	$4\text{-MeOC}_6\text{H}_4$			5t	94 (>99:1)	92
7	Ph	4-MeOC ₆ H ₄	Ε.	toluene/	5u	95 (>99:1)	85
8	$4-MeOC_6H_4$	Ph	Et (2:)	$CH_2Cl_2^{[d]}$	5 v	97 (>99:1)	87
9	PhCH=CH ₂	Ph	(3i)		5 w	87 (97:3)	86

[a] Yield of isolated product. [b] The diastereomeric ratio was determined by ¹H NMR spectroscopic analysis. [c] The enantiomeric excess of the major *trans-5* isomer was determined by HPLC analysis using a chiral column (DAICEL Chiralpak AD-H or Chiralcel OD-H) with hexane/2-propanol as solvent. [d] 1:1 v/v.

Conclusions

An efficient method for the synthesis of optically active 3,4-dihydropyran-2-one derivatives was established through

Experimental Section

All melting points were determined on a Yanagimoto micro melting point apparatus (Yanaco MP-S3) and were not corrected. IR spectra were recorded on a SensIR Technologies TravelIRTM Portable FTIR spectrometer (attenuated total reflection). ¹H NMR spectra were recorded on a JEOL JNM-EX270 L (270 MHz) spectrometer; chemical shifts (δ) are reported in parts per million relative to tetramethylsilane. Splitting patterns are designated as s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), or br (broad). ¹³C NMR spectra were recorded a JEOL JNM-EX270 L (68 MHz) spectrometer with complete proton decoupling. Chemical shifts are reported in parts per million relative to tetramethylsilane with the solvent resonance as the internal standard. The optical rotations were measured with a JASCO P-1020 polarimeter. High-resolution mass spectra (HRMS) were recorded

on a JEOL JMS-700 mass spectrometer. Elemental analysis was performed on a Yanagimoto CHN CORDER MT-6. X-ray crystallographic analysis was undertaken on a Rigaku AFC7R diffractometer with graphite monochromated $Cu_{K\alpha}$ radiation. Analytical high-performance liquid

chromatography (HPLC) was performed on a Hitachi LC-Organizer, L-4000 UV Detector, L-6200 Intelligent Pump, and D-2500 Chromato-Integrator. The enantiomeric excess (ee) was determined by HPLC analysis using a chiral column (DAICEL Chiralcel OD-H or Chiralpak AD-H, $\phi = 4.6 \times 250$ mm) with hexane/2-propanol as solvent. Analytical TLC was performed on Merck precoated TLC plates (silica gel 60 GF254, 0.25 mm). Column chromatography was conducted on Merck silica gel 60 and preparative thin-layer chromatography (PTLC) was carried out on Wakogel B-5F. Reactions were carried out in dry solvents under an argon atmosphere, unless otherwise noted. Dehydrated solvents were purchased from Kanto Chemical. All reagents were purchased from Tokyo Kasei Kogyo, Kanto Chemical, Kokusan Chemical, Wako Pure Chemical Industries, or Aldrich. Amberlyst A-26 (OH-) was purchased from Aldrich and used without further purification. Cinchonidine and cinchonine were purchased from Tokyo Kasei Kogyo or Wako Pure Chemical Industries and used after purification by silica-gel column chromatography with MeOH/EtOAc (1:1 v/v) as solvent to remove impurities, 10,11-dihydroderivatives. α,β -Unsaturated ketones (2 f, g, and i) were prepared according to reported procedures.^[15] All ketene silyl acetals 3 were prepared from the corresponding phenyl carboxylates by known methods.^[16]

Typical procedure for the preparation of cinchonidine-derived chiral quaternary ammonium phenoxide 1 (Scheme 2 and Table 2, entry 6): Ion-exchange resin Amberlyst A-26 (OH⁻) (1.0 g) was added to a stirred solution of N-(9-anthracenylmethyl)-O-[3,5-bis(trifluoromethyl)benzyl]cinchonidinium bromide $^{[17]}$ (1.0 g, 1.26 mmol) in methanol (10 mL) at room temperature. The mixture was stirred for 10 h at the same temperature, filtered, and washed with methanol. Phenol (119 mg, 1.26 mmol) was added to the filtrate, and the resulting mixture was co-evaporated three times with benzene. Crystallization of the residue from diethyl ether afforded a pale-yellow solid, which was collected by filtration and dried under reduced pressure to form cinchonidine-derived chiral quaternary ammonium salt **1k** (Ar 1 =9-anthracenyl, R 5 =3,5-bis(trifluoromethyl)benzyl) as a quaternary ammonium phenoxide-phenol complex^[8] (0.49 g, 43% yield). The yield of 1k increased to 89% when phenol (237 mg, 2.52 mmol, 2 equiv) was used in the above-mentioned procedure. This reagent can be handled in air and stored in a sealed bottle without decomposition for at least one month at room temperature. Pale-yellow powder; $[a]_D^{29} = -97.2^{\circ}$ (c=1.00 in CHCl₃); m.p. 117 °C (decomp.); IR (ATR): $\tilde{v} = 1592$, 1491, 1476, 1347, 1276, 1170, 1132 cm⁻¹; ¹H NMR (CD₃OD): $\delta = 9.02$ (d, J = 4.3 Hz, 1H), 8.88 (s, 1H), 8.64 (d, J = 9.2 Hz, 1H), 8.56-8.51 (m, 1H), 8.31-7.89 (m, 10H), 7.79 (t, J = 7.6 Hz, 1H), 7.63(t, J=7.6 Hz, 1 H), 7.54 (t, J=7.6 Hz, 1 H), 7.24 (t, J=7.6 Hz, 1 H), 7.15(br s, 1H), 7.00 (t, J=7.3 Hz, 4H), 6.65 (d, J=7.3 Hz, 4H), 6.54 (t, J=7.3 Hz, 4H), 6.55 7.3 Hz, 2H), 6.45 (d, J = 13.8 Hz, 1H), 5.85 (d, J = 13.8 Hz, 1H), 5.73–5.59 (m, 1 H), 5.24 (d, J=12.4 Hz, 1 H), 5.12 (d, J=12.4 Hz, 1 H), 5.01–4.90 (m, 2H), 4.50-4.29 (m, 2H), 3.71-3.60 (m, 1H), 3.21 (t, J=11.6 Hz, 1H),2.98-2.84 (m, 1H), 2.70-2.59 (m, 1H), 2.44-2.36 (m, 1H), 2.20-2.08 (m, 1H), 2.00-1.97 (m, 1H), 1.79-1.58 ppm (m, 2H); ¹³C NMR (CD₃OD): $\delta = 162.8, 151.0, 149.2, 142.2, 141.5, 138.1, 134.6, 134.3, 134.0, 133.4, 132.9,$ $132.9,\ 132.5,\ 131.5,\ 131.3,\ 131.1,\ 130.6,\ 130.0,\ 129.4,\ 129.4,\ 129.2,\ 129.1,$ 128.7, 126.8, 126.6, 126.6, 126.2, 126.0, 124.9, 124.3, 123.9, 123.2, 123.2, 123.1, 122.6, 121.8, 118.6, 118.5, 117.9, 117.8, 117.6, 116.6 (135-115: multiple peaks), 71.1, 70.4, 63.4, 57.6, 53.8, 39.4, 27.3, 26.2, 23.1 ppm; HRMS (ESI+): m/z calcd for $[C_{43}H_{37}F_6N_2O]$ +: 711.2810; found: 711.2802; elemental analysis: calcd for C₄₉H₄₂F₆N₂O₂·C₆H₅OH: C 73.48, H 5.38, N 3.12; found: C 73.42, H 5.45, N 3.06.

1a (Ar¹=Ph, Ar²=Ph): Pale-yellow powder; $[\alpha]_D^{20} = -109^{\circ}$ (c = 1.00 in CHCl₃); m.p. 144 °C (decomp.); IR (ATR): $\tilde{v} = 1592$, 1492, 1476, 1457, 1309, 1214, 1067 cm⁻¹; ¹H NMR (CD₃OD): $\delta = 9.01$ (d, J = 4.3 Hz, 1H), 8.27–8.16 (m, 2H), 7.96–7.79 (m, 3H), 7.61–7.37 (m, 10H), 7.02 (t, J = 7.3 Hz, 2H), 6.67 (d, J = 7.3 Hz, 2H), 6.57 (t, J = 7.3 Hz, 1H), 6.43 (s, 1H), 5.70–5.57 (m, 1H), 5.11–4.92 (m, 2H), 4.84 (d, J = 11.3 Hz, 1H), 4.74 (d, J = 12.4 Hz, 1H), 4.62 (d, J = 12.4 Hz, 1H), 4.60 (d, J = 11.3 Hz, 1H), 4.16–4.03 (m, 1H), 3.97–3.88 (m, 1H), 3.55–3.21 (m, 3H), 2.69–2.56 (m, 1H), 2.47–2.37 (m, 1H), 2.22–2.09 (m, 1H), 2.08–2.00 (m, 1H), 1.88–1.74 (m, 1H), 1.60–1.48 ppm (m, 1H); ¹³C NMR (CD₃OD): $\delta = 162.7$, 150.9, 149.1, 142.8, 138.3, 137.5, 134.6, 131.7, 131.3, 130.5, 130.2, 130.1, 130.0, 129.9, 129.3, 129.2, 128.1, 126.8, 123.7, 121.6, 117.8, 117.7, 117.5,

73.0, 72.3, 69.5, 65.3, 62.0, 52.6, 38.9, 28.0, 25.8, 22.8 ppm; HRMS (ESI+): m/z calcd for $[C_{33}H_{35}N_2O]^+$: 475.2749; found: 475.2760.

1b (Ar¹=4-CF₃C₆H₄, Ar²=Ph): Catalyst **1b** was obtained as a quaternary ammonium phenoxide-phenol complex. Pale-yellow powder; $[\alpha]_D^{20}$ = -103° (c=1.00 in CHCl₃); m.p. 129 °C (decomp.); IR (ATR): $\tilde{v}=1587$, 1465, 1325, 1233, 1167, 1131, 1116, 1067 cm⁻¹; ¹H NMR (CD₃OD): δ = 9.01 (d, J=4.6 Hz, 1H), 8.26–8.15 (m, 2H), 8.01–7.79 (m, 5H), 7.69 (d, J = 7.8 Hz, 1 H), 7.60–7.37 (m, 5 H), 7.04 (t, J = 7.3 Hz, 4 H), 6.68 (d, J =7.3 Hz, 4H), 6.60 (t, J=7.3 Hz, 2H), 6.42 (s, 1H), 5.70–5.57 (m, 1H), 5.11-4.92 (m, 2H), 4.85 (d, J=11.3 Hz, 1H), 4.81 (d, J=12.2 Hz, 1H), 4.66 (d, J=12.2 Hz, 1H), 4.62 (d, J=11.3 Hz, 1H), 4.20–4.04 (m, 1H), 3.99-3.88 (m, 1H), 3.57-3.20 (m, 3H), 2.70-2.57 (m, 1H), 2.51-2.38 (m, 1H), 2.22-2.09 (m, 1H), 2.08-2.01 (m, 1H), 1.89-1.74 (m, 1H), 1.61-1.48 ppm (m, 1H); 13 C NMR (CD₃OD): δ =162.2, 151.0, 149.1, 142.6, 138.2, 137.5, 135.5, 134.1, 133.7, 133.2, 132.7, 132.4, 132.4, 131.4, 131.1, 130.6, 130.2, 130.1, 130.0, 129.9, 129.3, 129.2, 127.1, 126.8, 123.6, 123.1, 118.0, 117.7 (135-115: multiple peaks), 73.0, 72.3, 69.8, 64.3, 62.1, 52.9, 38.8, 27.8, 25.7, 22.8 ppm; HRMS (ESI⁺): m/z calcd for $[C_{34}H_{34}F_3N_2O]^+$: 543.2623: found: 543.2641.

1c $(Ar^1 = 3.5 - (tBu)_2 C_6 H_3, Ar^2 = Ph)$: Pale-yellow powder; $[\alpha]_D^{21} = -80.1^{\circ}$ $(c=1.00 \text{ in CHCl}_3)$; m.p. 89°C (decomp.); IR (ATR): $\tilde{v}=2955$, 1739, 1587, 1464, 1365, 1230, 1216 cm⁻¹; ¹H NMR (CD₃OD): δ =9.01 (d, J= 4.3~Hz,~1~H),~8.24-8.16~(m,~2~H),~7.98-7.82~(m,~3~H),~7.65-7.28~(m,~8~H),7.02 (t, J = 7.3 Hz, 2H), 6.67 (d, J = 7.3 Hz, 2H), 6.56 (t, J = 7.3 Hz, 1H), 6.42 (s, 1H), 5.71-5.53 (m, 1H), 5.10-4.84 (m, 3H), 5.10-4.84 (m, 3H), 4.72-4.49 (m, 3H), 4.18-3.99 (m, 1H), 3.97-3.79 (m, 1H), 3.50-3.21 (m, 3H), 2.72-2.57 (m, 1H), 2.50-2.36 (m, 1H), 2.24-1.99 (m, 2H), 1.91-1.74 (m, 1H), 1.61–1.47 (m, 1H), 1.38 ppm (s, 18H); 13 C NMR (CD₃OD): δ = 161.6, 153.2, 151.0, 149.1, 142.7, 138.4, 137.5, 131.4, 130.6, 130.3, 130.1, 130.0, 129.3, 128.9, 127.3, 126.8, 125.8, 123.6, 121.6, 118.3, 117.5, 117.4, 73.1, 72.4, 69.6, 66.0, 61.9, 52.5, 38.9, 35.9, 31.8, 27.9, 25.8, 22.9 ppm; HRMS (ESI⁺): m/z calcd for $[C_{41}H_{51}N_2O]^+$: 587.4001; found: 587.4001. **1d**: (Ar¹=1-naphthyl, Ar²=Ph): Pale-yellow powder; $[\alpha]_D^{21} = -156^{\circ}$ (c= 1.00 in CHCl₃); m.p. 114 °C (decomp.); IR (ATR): $\tilde{v} = 1590$, 1467, 1234, 1067, 1024 cm⁻¹; ¹H NMR (CD₃OD): $\delta = 9.03$ (d, J = 4.6 Hz, 1H), 8.46– 8.37 (m, 1H), 8.21–8.17 (m, 1H), 8.12 (d, J=8.1 Hz, 1H), 8.06–7.97 (m, 3 H), 7.96–7.31 (m, 3 H), 7.69–7.42 (m, 8 H), 7.03 (t, J = 7.3 Hz, 2 H), 6.73 (s, 1H), 6.68 (d, J=7.3 Hz, 2H), 6.59 (t, J=7.3 Hz, 1H), 5.72–5.59 (m, 1 H), 5.48 (d, J = 13.0 Hz, 1 H), 5.28 (d, J = 13.0 Hz, 1 H), 5.10–4.89 (m, 3H), 4.77 (d, J=11.1 Hz, 1H), 4.30-4.17 (m, 2H), 3.77-3.65 (m, 1H), 3.41 (t, J=12.4 Hz, 1H), 3.18-3.05 (m, 1H), 2.60-2.41 (m, 2H), 2.20-2.09 (m, 1H), 2.08–1.97 (m, 1H), 1.75–1.49 ppm (m, 2H); 13 C NMR (CD₃OD): δ = 161.9, 150.9, 149.1, 142.7, 138.3, 137.8, 135.6, 134.4, 133.1, $131.4,\ 130.5,\ 130.1,\ 130.0,\ 129.8,\ 129.7,\ 129.4,\ 129.2,\ 128.8,\ 127.4,\ 126.8,$ 126.2, 124.2, 124.0, 121.6, 118.2, 117.6, 117.5, 74.1, 72.5, 69.7, 62.5, 61.8, 53.4, 39.1, 27.6, 25.9, 23.1 ppm; HRMS (ESI+): m/z calcd for [C₃₇H₃₇N₂O]+: 525.2906; found: 525.2907.

1e (Ar¹=2-naphthyl, Ar²=Ph): Pale-yellow powder; $[\alpha]_D^{12} = -113^\circ$ (c = 1.00 in CHCl₃); m.p. 115 °C (decomp.); IR (ATR): $\bar{v} = 1590$, 1456, 1067, 1023 cm⁻¹; ¹H NMR (CD₃OD): $\delta = 9.02$ (d, J = 4.6 Hz, 1H), 8.25–8.17 (m, 2H), 8.12 (d, J = 8.1 Hz, 1H), 8.06–7.77 (m, 7H), 7.68–7.40 (m, 8H), 7.03 (t, J = 7.3 Hz, 2H), 6.67 (d, J = 7.3 Hz, 2H), 6.58 (t, J = 7.3 Hz, 1H), 6.49 (s, 1H), 5.73–5.59 (m, 1H), 5.08 (d, J = 17.0 Hz, 1H), 4.99 (d, J = 10.5 Hz, 1H), 4.93–4.85 (m, 2H), 4.77 (d, J = 12.4 Hz, 1H), 4.64 (d, J = 11.3 Hz, 1H), 4.24–4.12 (m, 1H), 4.04–3.92 (m, 1H), 3.61–3.27 (m, 3H), 2.69–2.57 (m, 1H), 2.52–2.39 (m, 1H), 2.25–2.12 (m, 1H), 2.10–2.02 (m, 1H), 1.86–1.74 (m, 1H), 1.63–1.51 ppm (m, 1H); ¹³C NMR (CD₃OD): $\delta = 162.4$, 151.0, 149.1, 142.9, 138.4, 137.6, 135.2, 135.2, 134.3, 131.3, 130.6, 130.4, 130.3, 130.2, 130.0, 129.3, 129.2, 128.9, 128.7, 128.2, 126.8, 125.3, 123.6, 121.6, 117.9, 117.7, 117.5, 72.4, 69.5, 65.5, 62.2, 52.8, 38.9, 28.0, 25.8, 22.8 ppm; HRMS (ESI⁺): m/z calcd for $[C_{37}H_{37}N_2O]$ †: 525.2906; found: 525.2910.

1f (Ar¹=9-anthracenyl, Ar²=Ph): Pale-yellow powder; $[\alpha]_D^{22}=-136^{\circ}$ (c=1.00 in CHCl₃); m.p. 94 °C (decomp.); IR (ATR): $\tilde{v}=1591$, 1477, 1453, 1143, 1067, 1025 cm⁻¹; ¹H NMR (CD₃OD): δ =9.06 (d, J=4.6 Hz, 1H), 8.85 (s, 1H), 8.67 (d, J=8.9 Hz, 1H), 8.63–8.55 (m, 1H), 8.26–8.17 (m, 3H), 8.10–8.03 (m, 2H), 8.00–7.89 (m, 2H), 7.81–7.47 (m, 8 H), 7.38–7.31 (m, 1H), 7.05–6.98 (m, 3H), 6.66 (d, J=7.3 Hz, 2H), 6.56 (t, J=

7.3 Hz, 1 H), 6.25 (d, J=13.8 Hz, 1 H), 5.84 (d, J=13.8 Hz, 1 H), 5.71–5.58 (m, 1 H), 5.03–4.90 (m, 4 H), 4.51–4.31 (m, 2 H), 3.73–3.62 (m, 1 H), 3.13 (t, J=10.8 Hz, 1 H), 2.89–2.77 (m, 1 H), 2.59–2.47 (m, 1 H), 2.41–2.31 (m, 1 H), 2.18–2.03 (m, 1 H), 1.96–1.90 (m, 1 H), 1.69–1.46 ppm (m, 2 H); 13 C NMR (CD₃OD): δ =162.6, 150.9, 149.2, 142.7, 138.3, 138.0, 134.6, 134.3, 133.8, 132.9, 132.8, 131.5, 131.1, 131.1, 130.6, 130.2, 130.0, 129.7, 129.3, 129.2, 129.1, 127.0, 126.5, 126.3, 125.0, 124.6, 121.8, 118.6, 117.8, 117.8, 117.7, 72.6, 70.3, 63.3, 57.5, 53.8, 39.5, 27.3, 26.2, 23.3 ppm; HRMS (ESI+): m/z calcd for $[C_{41}H_{39}N_2O]^+$: 575.3062; found: 575.3062.

1g (Ar¹=9-anthracenyl, Ar²=4-MeC₆H₄): Pale-yellow powder; $[\alpha]_D^{22}$ = -121° (c=1.00 in CHCl₃); m.p. 97°C (decomp.); IR (ATR): \tilde{v} =1589, 1476, 1452, 1138, 1067 cm⁻¹; ¹H NMR (CD₃OD): δ =9.06 (d, J=4.6 Hz, 1H), 8.85 (s, 1H), 8.66 (d, J = 8.9 Hz, 1H), 8.62–8.54 (m, 1H), 8.25–8.17 (m, 3H), 8.07-8.02 (m, 2H), 7.99-7.89 (m, 2H), 7.82-7.74 (m, 1H), 7.68-7.54 (m, 4H), 7.45–7.36 (m, 3H), 7.04–6.97 (m, 3H), 6.65 (d, J = 7.3 Hz, 2H), 6.54 (t, J=7.3 Hz, 1H), 6.19 (d, J=13.8 Hz, 1H), 5.83 (d, J=13.813.8 Hz, 1H), 5.70–5.57 (m, 1H), 4.99–4.90 (m, 3H), 4.84 (d, J=11.3 Hz, 1H), 4.49-4.29 (m, 2H), 3.70-3.59 (m, 1H), 3.09 (t, J=10.8 Hz, 1H), 2.89-2.76 (m, 1H), 2.57-2.44 (m, 1H), 2.42 (s, 3H), 2.40-2.25 (m, 1H), 2.17–2.02 (m, 1 H), 1.95–1.88 (m, 1 H), 1.65–1.43 ppm (m, 2 H); ¹³C NMR (CD₃OD): $\delta = 162.8$, 150.9, 149.2, 142.8, 139.8, 138.3, 134.9, 134.6, 134.2, 133.8, 132.9, 132.8, 131.4, 131.1, 131.1, 130.8, 130.6, 130.0, 129.5, 129.3, $129.3,\ 129.0,\ 127.0,\ 126.5,\ 126.4,\ 125.0,\ 124.6,\ 124.1,\ 121.8,\ 118.6,\ 117.9,$ 117.7, 117.6, 72.4, 70.4, 63.2, 57.6, 53.9, 39.4, 27.3, 26.2, 23.2, 21.4 ppm; HRMS (ESI⁺): m/z calcd for $[C_{42}H_{41}N_2O]^+$: 589.3219; found: 589.3230. **1h** (Ar¹=9-anthracenyl, Ar²=4-MeOC₆H₄): Pale-yellow powder; $[\alpha]_D^{22}$ = -134° (c=1.00 in CHCl₃); m.p. 92 °C (decomp.); IR (ATR): $\tilde{v}=1611$, 1586, 1512, 1464, 1302, 1249, 1066, 1028 cm⁻¹; ¹H NMR (CD₃OD): δ = 9.06 (d, J=4.9 Hz, 1H), 8.86 (s, 1H), 8.63 (d, J=8.9 Hz, 1H), 8.62–8.53 (m, 1H), 8.27-8.18 (m, 3H), 8.08-8.01 (m, 2H), 8.00-7.89 (m, 2H), 7.82-7.74 (m, 1H), 7.66–7.48 (m, 5H), 7.11 (d, J=8.4 Hz, 1H), 7.04–6.96 (m, 3H), 6.65 (d, J = 7.3 Hz, 2H), 6.52 (t, J = 7.3 Hz, 1H), 6.17 (d, J = 13.8 Hz, 1H), 5.82 (d, J=13.8 Hz, 1H), 5.69–5.56 (m, 1H), 4.98–4.86 (m, 3H), 4.78 (d, J=11.3 Hz, 1 H), 4.47-4.26 (m, 2 H), 3.83 (s, 3 H), 3.66-3.55 (m, 1H), 3.07 (t, J=10.8 Hz, 1H), 2.90–2.78 (m, 1H), 2.59–2.45 (m, 1H), 2.39-2.25 (m, 1 H), 2.17-2.04 (m, 1 H), 1.94-1.87 (m, 1 H), 1.68-1.46 ppm (m, 2H); 13 C NMR (CD₃OD): $\delta = 163.1$, 161.4, 150.9, 149.2, 142.9, 142.5, 138.2, 134.6, 134.2, 133.8, 132.8, 131.4, 131.1, 131.1, 130.7, 130.6, 129.9, 129.8, 129.3, 129.1, 127.0, 126.5, 126.4, 125.0, 124.6, 124.0, 121.9, 118.6, 118.0, 117.7, 117.4, 115.5, 114.7, 72.2, 70.5, 63.0, 57.6, 55.8, 54.0, 39.4, 27.3, 26.1, 23.1 ppm; HRMS (ESI⁺): m/z calcd for $[C_{42}H_{41}N_2O_2]^+$: 605.3168; found: 605.3176.

 $\textbf{1i} \ (Ar^1\!=\!9\text{-anthracenyl}, \ Ar^2\!=\!4\text{-ClC}_6H_4)\text{: Pale-yellow powder}; \ [\alpha]_D^{22}\!=\!$ -108° (c=1.00 in CHCl₃); m.p. 103 °C (decomp.); IR (ATR): $\tilde{v}=1590$, 1492, 1478, 1452, 1065 cm⁻¹; ¹H NMR (CD₃OD): δ =9.06 (d, J=4.1 Hz, 1H), 8.86 (s, 1H), 8.68 (d, J = 8.9 Hz, 1H), 8.62–8.54 (m, 1H), 8.26–8.18 (m, 3H), 8.09 (d, J=8.9 Hz, 1H), 8.03 (d, J=4.6 Hz, 1H), 8.00-7.89 (m, 3H)2H), 7.82-7.54 (m, 7H), 7.43-7.37 (m, 1H), 7.07-6.95 (m, 3H), 6.65 (d, J=7.3 Hz, 2H), 6.53 (t, J=7.3 Hz, 1H), 6.29 (d, J=13.8 Hz, 1H), 5.85 (d, J = 13.8 Hz, 1 H), 5.71–5.57 (m, 1 H), 4.99–4.89 (m, 4 H), 4.51–4.26 (m, 2H), 3.72-3.62 (m, 1H), 3.13 (t, J=11.9 Hz, 1H), 2.90-2.77 (m, 1H), 2.59-2.47 (m, 1H), 2.41-2.29 (m, 1H), 2.18-2.02 (m, 1H), 1.95-1.89 (m, 1H), 1.68–1.45 ppm (m, 2H); 13 C NMR (CD₃OD): $\delta = 162.9$, 150.9, 149.2, 142.6, 138.2, 136.8, 135.4, 134.6, 134.3, 133.8, 132.9, 132.8, 131.5, 131.2, 131.1, 130.8, 130.6, 130.2, 130.0, 129.4, 129.0, 127.0, 126.5, 126.4, 125.0, 124.4, 124.1, 121.7, 118.6, 117.9, 117.7, 117.6, 71.8, 70.3, 63.3, 57.5, 53.8, 39.4, 27.3, 26.2, 23.2 ppm; HRMS (ESI+): m/z calcd for [C₄₁H₃₈ClN₂O]+: 609.2673; found: 609.2679.

1j (Ar¹ = 9-anthracenyl, Ar² = 4-NO₂C₆H₄): Catalyst **1j** was obtained as a quaternary ammonium phenoxide-phenol complex. Pale-yellow powder; $[\alpha]_D^{19} = -99.2^{\circ}$ (c = 1.00 in CHCl₃); m.p. 99 °C (decomp.); IR (ATR): $\tilde{\nu} = 1591$, 1520, 1473, 1344, 1257, 1067 cm⁻¹; ¹H NMR (CD₃OD): $\delta = 9.05$ (d, J = 4.6 Hz, 1H), 8.86 (s, 1H), 8.67 (d, J = 8.9 Hz, 1H), 8.61–8.54 (m, 1H), 8.43 (d, J = 8.6 Hz, 2H), 8.28–8.13 (m, 4H), 8.09–7.90 (m, 5H), 7.83–7.76 (m, 1H), 7.66–7.59 (m, 1H), 7.58–7.51 (m, 1H), 7.34–7.26 (m, 1H), 7.12 (br s, 1H), 7.00 (t, J = 7.3 Hz, 4H), 6.65 (d, J = 7.3 Hz, 4H), 6.54 (t, J = 7.3 Hz, 2H), 6.38 (d, J = 14.0 Hz, 1H), 5.85 (d, J = 14.0 Hz, 1H), 5.73–5.59 (m, 1H), 5.18 (d, J = 12.7 Hz, 1H), 5.04 (d, J = 12.7 Hz, 1H), 5.02–4.95

(m, 2H), 4.53–4.41 (m, 1H), 4.40–4.29 (m, 1H), 3.76–3.63 (m, 1H), 3.20 (t, J=10.8 Hz, 1H), 2.93–2.78 (m, 1H), 2.64–2.54 (m, 1H), 2.43–2.34 (m, 1H), 2.21–2.04 (m, 1H), 2.01–1.95 (m, 1H), 1.73–1.52 ppm (m, 2H); 13 C NMR (CD₃OD): δ =162.6, 151.0, 149.3, 149.2, 145.4, 142.3, 138.2, 134.6, 134.3, 133.9, 132.9, 132.8, 131.5, 131.2, 131.1, 131.0, 130.7, 130.0, 129.5, 129.4, 129.2, 128.9, 126.9, 126.6, 126.5, 126.4, 125.1, 124.9, 124.3, 124.0, 121.5, 118.6, 117.8, 117.8, 71.3, 70.3, 63.5, 57.5, 53.8, 39.4, 27.3, 26.3, 23.2 ppm; HRMS (ESI⁺): m/z calcd for [C₄₁H₃₈N₃O₃]⁺: 620.2913; found: 620.2920.

11 (Ar¹=9-anthracenyl, Ar²=3,5-(CF₃)₂C₆H₃): Catalyst 11 was obtained as a quaternary ammonium phenoxide-phenol complex. Pale-yellow powder; $[\alpha]_D^{20} = +85.2^{\circ}$ (c=1.00 in CHCl₃); m.p. 103°C (decomp.); IR (ATR): $\tilde{v} = 1592$, 1466, 1363, 1277, 1175, 1130 cm⁻¹; ¹H NMR (CD₃OD): $\delta = 9.05$ (d, J = 4.9 Hz, 1H), 8.87 (s, 1H), 8.78 (d, J = 8.9 Hz, 1H), 8.66– 8.56 (m, 1H), 8.33 (s, 2H), 8.28–8.17 (m, 4H), 8.07 (d, J = 4.6 Hz, 1H), 7.99 (dd, J = 6.5, 3.2 Hz, 2H), 7.89–7.81 (m, 2H), 7.65 (t, J = 6.8 Hz, 1H), 7.47 (t, J = 6.8 Hz, 1H), 7.10 (br s, 1H), 7.01 (t, J = 7.3 Hz, 4H), 6.83 (t, J=7.6 Hz, 1 H), 6.66 (d, J=7.3 Hz, 4 H), 6.56 (t, J=7.3 Hz, 2 H), 6.16– 5.94 (m, 3H), 5.21-4.92 (m, 4H), 4.53-4.41 (m, 1H), 4.25-4.10 (m, 2H), 3.19 (t, *J* = 11.3 Hz, 1 H), 2.86–2.69 (m, 2 H), 2.34–2.21 (m, 1 H), 1.95–1.73 (m, 2H), 1.71–1.58 (m, 1H), 1.42–1.29 ppm (m, 1H); ¹³C NMR (CD_3OD) : $\delta = 162.8$, 151.0, 149.3, 141.6, 141.4, 137.0, 134.5, 134.3, 134.1, 133.9, 133.6, 133.1, 133.0, 132.8, 132.6, 131.5, 131.4, 131.0, 130.5, 130.0, $129.4,\ 129.3,\ 129.2,\ 128.9,\ 128.4,\ 126.8,\ 126.6,\ 126.1,\ 125.1,\ 124.2,\ 124.0,$ 123.3, 122.7, 121.5, 118.5, 118.0, 117.9, 117.6 (135-115: multiple peaks), 76.2, 70.8, 69.0, 59.1, 57.5, 56.6, 38.8, 27.2, 24.7, 23.4 ppm; HRMS (ESI+): m/z calcd for $[C_{43}H_{37}F_6N_2O]^+$: 711.2810; found: 711.2807.

1m (R⁵=H, Ar¹=Ph): Pale-yellow powder; $[\alpha]_D^{20} = -92.1^{\circ}$ (c=1.00 in CHCl₃); m.p. 118°C (decomp.); IR (ATR): \bar{v} =3047, 1585, 1469, 1257, 1161 cm⁻¹; ¹H NMR (CD₃OD): δ =8.79 (d, J=4.6 Hz, 1H), 8.11 (d, J=7.8 Hz, 1H), 7.99 (d, J=7.8 Hz, 1H), 7.84 (d, J=4.6 Hz, 1H), 7.78–7.61 (m, 2 H), 7.60–7.50 (m, 2 H), 7.49–7.38 (m, 3 H), 6.87 (t, J=7.3 Hz, 2 H), 6.60–6.46 (m, 3 H), 6.41 (t, J=7.3 Hz, 1H), 5.62–5.41 (m, 1 H), 5.12–4.71 (m, 5 H), 4.43–4.23 (m, 1H), 3.92–3.74 (m, 1H), 3.58–3.42 (m, 1 H), 3.41–3.11 (m, 2 H), 2.62–2.45 (m, 1 H), 2.21–1.99 (m, 2 H), 1.96–1.83 (m, 1 H), 1.78–1.59 (m, 1 H), 1.32–1.15 ppm (m, 1 H); ¹³C NMR (CD₃OD): δ=163.3, 150.8, 148.5, 147.7, 138.5, 134.7, 131.5, 130.9, 130.2, 130.0, 129.1, 128.8, 128.5, 125.9, 123.9, 121.3, 118.2, 117.3, 117.3, 69.7, 66.1, 65.1, 61.9, 52.5, 39.0, 28.0, 25.9, 22.5; HRMS (FAB⁺): m/z calcd for [C₂₆H₂₉N₂O]⁺: 385.2280; found: 385.2272.

1n (R⁵=H, Ar¹=9-anthracenyl): Pale-yellow powder; $[\alpha]_D^{20}=-324^{\circ}$ (c=1.00 in CHCl₃); m.p. 120 °C (decomp.); IR (ATR): $\bar{v}=3047$, 1584, 1492, 1467, 1253, 1159 cm⁻¹; ¹H NMR (CD₃OD): δ =8.90 (d, J=4.9 Hz, 1 H), 8.78–8.66 (m, 2 H), 8.62–8.48 (m, 2 H), 8.20–8.05 (m, 3 H), 8.03 (d, J=4.9 Hz, 1 H), 7.92–7.64 (m, 4 H), 7.63–7.50 (m, 2 H), 7.01 (br s, 1 H), 6.88 (t, J=8.1 Hz, 2 H), 6.62 (d, J=8.1 Hz, 2 H), 6.46–6.30 (m, 2 H), 5.78 (d, J=13.8 Hz, 1 H), 5.66–5.53 (m, 1 H), 5.00–4.83 (m, 3 H), 4.78–4.61 (m, 1 H), 4.42–4.32 (m, 1 H), 3.80–3.68 (m, 1 H), 3.08 (t, J=11.6 Hz, 1 H), 2.78–2.62 (m, 1 H), 2.34–2.12 (m, 2 H), 2.09–1.94 (m, 1 H), 1.79 (br s, 1 H), 1.43–1.23 ppm (m, 2 H); ¹³C NMR (CD₃OD): δ =163.9, 150.8, 148.5, 147.9, 138.5, 134.5, 134.4, 133.4, 132.7, 132.7, 130.9, 130.9, 130.1, 129.9, 129.1, 129.1, 128.9, 126.4, 126.1, 125.3, 125.1, 124.2, 121.5, 119.1, 118.4, 117.4, 116.9, 70.0, 67.2, 63.5, 56.6, 53.2, 39.5, 27.1, 26.2, 23.1 ppm; HRMS (FAB*): m/z calcd for [C₃4H₃₃N₂O]*: 485.2593; found: 485.2610.

10 (R⁵=H, Ar¹=3,5-(CF₃)₂C₆H₃): Pale-yellow powder; $[\alpha]_D^{23}=-105^\circ$ (c=1.00 in CHCl₃); m.p. 107 °C (decomp.); IR (ATR): $\bar{v}=1588$, 1471, 1373, 1278, 1174, 1129 cm⁻¹; ¹H NMR (CD₃OD): $\delta=8.79$ (d, J=4.6 Hz, 1H), 8.28 (s, 2H), 8.18–8.08 (m, 2H), 8.03–7.95 (m, 1H), 7.85 (d, J=4.6 Hz, 1H), 7.76–7.63 (m, 2H), 6.79 (t, J=7.3 Hz, 2H), 6.52–6.42 (m, 3H), 6.27 (t, J=7.3 Hz, 1H), 5.60–5.46 (m, 1H), 5.22 (d, J=12.4 Hz, 1H), 5.07–4.80 (m, 4H), 4.58–4.41 (m, 1H), 3.91–3.79 (m, 1H), 3.62–3.51 (m, 1H), 3.39–3.16 (m, 2H), 2.57 (br s, 1H), 2.21–2.02 (m, 2H), 1.93 (br s, 1H), 1.80–1.65 (m, 1H), 1.30–1.16 ppm (m, 1H); ¹³C NMR (CD₃OD): $\delta=165.6$, 150.9, 148.5, 148.0, 135.3, 135.2, 134.2, 133.7, 133.2, 132.7, 132.0, 131.9, 130.9, 130.4, 130.2, 129.9, 128.8, 126.4, 126.0, 125.5, 125.4, 125.3, 123.8, 122.4, 121.4, 119.1, 118.4, 117.4, 116.1 (135–115: multiple peaks), 70.5, 66.4, 63.3, 61.9, 52.8, 39.1, 27.9, 25.9, 22.6 ppm; HRMS (FAB+): m/z calcd for $[C_{28}H_{27}F_6N_2O]^+$: 521.2028; found: 521.2008.

1p (R⁵=H, Ar¹=3,5-(tBu)₂C₆H₃): Pale-yellow powder; $[\alpha]_D^2 = -55.3^\circ$ (c=1.00 in CHCl₃); m.p. 116 °C (decomp.); IR (ATR): \bar{v} =2954, 1587, 1469, 1363, 1249, 1205, 1161 cm⁻¹; ¹H NMR (CD₃OD): δ=8.90 (d, J=4.6 Hz, 1 H), 8.20 (d, J=8.1 Hz, 1 H), 8.11 (d, J=8.1 Hz, 1 H), 7.91 (d, J=4.6 Hz, 1 H), 7.88–7.73 (m, 3 H), 7.65 (br s, 1 H), 7.54–7.44 (m, 2 H), 6.97 (t, J=7.3 Hz, 2 H), 6.67–6.56 (m, 3 H), 6.49 (t, J=7.3 Hz, 1 H), 5.74–5.60 (m, 1 H), 5.15–4.85 (m, 6 H), 4.58–4.38 (m, 1 H), 3.99–3.85 (m, 1 H), 3.64–3.25 (m, 3 H), 2.70 (br s, 1 H), 2.36–2.13 (m, 2 H), 2.03 (br s, 1 H), 1.95–1.76 (m, 1 H), 1.36 ppm (s, 18 H); ¹³C NMR (CD₃OD): δ=164.0, 160.6, 153.1, 150.9, 148.6, 147.8, 138.7, 131.0, 130.2, 129.9, 128.9, 128.8, 127.8, 126.1, 125.6, 123.9, 121.2, 118.4, 117.3, 117.0, 69.5, 66.2, 65.9, 62.1, 52.8, 39.2, 35.9, 31.8, 28.1, 26.0, 22.5 ppm; HRMS (FAB+): m/z calcd for [C₃₄H₄₅N₂O]+: 497.3532; found: 497.3549.

1q (R⁵=H, Ar¹=3,5-[3,5-(CF₃)₂C₆H₃)₂C₆H₃): Pale-yellow powder; $[\alpha]_D^{23}$ = -83.4° (c=1.00 in CHCl₃); m.p. 154°C (decomp.); IR (ATR): \bar{v} =1586, 1473, 1371, 1281, 1239, 1168, 1128 cm⁻¹; ¹H NMR (CD₃OD): δ =8.84 (d, J=4.6 Hz, 1H), 8.37 (s, 4H), 8.26 (s, 1H), 8.16 (d, J=7.8 Hz, 1H), 8.09-7.96 (m, 5H), 7.89 (d, J=4.6 Hz, 1H), 7.83–7.68 (m, 2H), 6.85 (t, J=7.3 Hz, 2H), 6.63–6.45 (m, 3H), 6.33 (t, J=7.3 Hz, 1H), 5.64–5.51 (m, 1H), 5.26 (d, J=12.4 Hz, 1H), 5.08–4.82 (m, 4H), 4.62–4.45 (m, 1H), 3.92–3.79 (m, 1H), 3.63–3.37 (m, 2H), 3.28–3.19 (m, 1H), 2.68–2.56 (m, 1H), 2.30–2.08 (m, 2H), 1.99 (br s, 1H), 1.89–1.71 (m, 1H), 1.40–1.21 ppm (m, 1H); ¹³C NMR (CD₃OD): δ =165.0, 150.9, 148.5, 148.1, 143.3, 141.5, 138.6, 134.1, 133.9, 133.6, 133.1, 132.6, 131.0, 130.9, 130.7, 130.3, 129.9, 129.6, 129.1, 128.8, 126.7, 126.0, 123.6, 122.7, 122.7, 122.6, 121.4, 118.8, 117.3, 116.4 (135–115: multiple peaks), 70.4, 66.5, 64.6, 62.4, 52.8, 39.3, 28.0, 26.0, 22.6 ppm; HRMS (FAB+): m/z calcd for [C₄₂H₃₃F₁₂N₂O]+: 809.2402; found: 809.2396.

Typical procedure for the synthesis of optically active 3,4-dihydropyran-2-ones 5 by using cinchonidine-derived catalyst $1\mathbf{k}$ (Table 3, entry 1): A solution of chalcone $2\mathbf{a}$ (62.5 mg, 0.3 mmol) in THF (1.4 mL) and a solution of ketene silyl acetal $3\mathbf{a}$ (113 mg, 0.48 mmol) in THF (0.6 mL) were added successively to a stirred solution of cinchonidine-derived catalyst $1\mathbf{k}$ (13.5 mg, 0.015 mmol) in THF (1.0 mL) at -78° C. After the mixture was stirred for 0.5–1 h at the same temperature, the reaction was quenched with aqueous HCl (1 m), and the mixture was extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na_2SO_4 , and evaporated. The crude product was purified by PTLC to give the corresponding $5\mathbf{a}$ (82.0 mg, 98 % yield). The enantiomeric excess of the product was determined by HPLC analysis (90 % ee).

5a: Colorless crystals; $[\alpha]_D^{25} = +182^{\circ}$ (c=1.00 in CHCl₃, 90% ee); m.p. 129–130 °C; IR (ATR): $\bar{\nu}=1762$, 1493, 1449, 1386, 1321, 1276, 1187, 1078, 1063 cm⁻¹; 1 H NMR (CDCl₃): $\delta=7.70$ –7.66 (m, 2H), 7.39–7.23 (m, 6H), 7.19–7.14 (m, 2H), 5.93 (d, J=5.4 Hz, 1H), 3.49 (d, J=5.4 Hz, 1H), 1.43 (s, 3H), 1.04 ppm (s, 3H); 13 C NMR (CDCl₃): $\delta=173.4$, 148.9, 138.7, 132.0, 128.9, 128.5, 128.4, 127.4, 124.4, 103.7, 50.1, 41.1, 26.0, 21.7 ppm; elemental analysis: calcd for C₁₉H₁₈O₂: C 81.99, H 6.52; found: C 82.03, H 6.59; HPLC analysis: DAICEL Chiralcel OD-H, hexane/2-propanol 50:1, $\lambda=254$ nm, flow rate = 1.0 mL min⁻¹, retention time = 9.6 min (4*S*) and 11.2 min (4*R*).

5b: Colorless crystals; $[\alpha]_{\rm D}^{27} = +150^{\circ}$ (c = 1.00 in CHCl₃, 84 % ee); m.p. 143–144 °C; IR (ATR): $\tilde{\nu} = 1756$, 1504, 1224, 1095, 1063 cm⁻¹; ¹H NMR (CDCl₃): $\delta = 7.70$ –7.66 (m, 2H), 7.45–7.35 (m, 3H), 7.16–7.10 (m, 2H), 7.02–6.95 (m, 2H), 5.91 (d, J = 5.4 Hz, 1H), 3.49 (d, J = 5.4 Hz, 1H), 1.43 (s, 3H), 1.03 ppm (s, 3H); ¹³C NMR (CDCl₃): $\delta = 173.2$, 162.0 (d, J = 245.6 Hz), 149.0, 134.5 (d, J = 2.9 Hz), 131.8, 130.0 (d, J = 7.8 Hz), 129.0, 128.4, 124.4, 115.4 (d, J = 21.3 Hz), 103.5, 49.3, 41.2, 25.9, 21.7 ppm; elemental analysis: calcd for C₁₉H₁₇FO₂: C 77.01, H 5.78; found: C 76.69, H 5.86; HPLC analysis: DAICEL Chiralpak AD-H, hexane/2-propanol 50:1, $\lambda = 254$ nm, flow rate = 1.0 mL min⁻¹, retention time = 11.7 min (major) and 14.0 min (minor).

5c: Colorless crystals; $[\alpha]_D^{30} = +149^{\circ}$ (c = 1.00 in CHCl₃, 82% ee); m.p. 115–117°C; IR (ATR): $\bar{v} = 1765$, 1508, 1232, 1090, 1064 cm⁻¹; ¹H NMR (CDCl₃): $\delta = 7.68$ –7.62 (m, 2H), 7.32–7.24 (m, 3H), 7.17–7.02 (m, 4H), 5.86 (d, J = 5.4 Hz, 1H), 3.49 (d, J = 5.4 Hz, 1H), 1.43 (s, 3H), 1.04 ppm (s, 3H); ¹³C NMR (CDCl₃): $\delta = 173.3$, 163.0 (d, J = 248.4 Hz), 148.1, 138.7, 128.5, 128.4, 128.2 (d, J = 2.8 Hz), 127.5, 126.4 (d, J = 8.4 Hz), 115.4 (d, J = 21.8 Hz), 103.4, 50.1, 41.1, 26.0, 21.7; elemental analysis: calcd for

 $C_{19}H_{17}FO_2$: C 77.01, H 5.78; found: C 76.88, H 5.82; HPLC analysis: DAICEL Chiralpak AD-H, hexane/2-propanol 50:1, λ =254 nm, flow rate=1.0 mLmin⁻¹, retention time=13.3 min (major) and 15.0 min (minor).

5 d: Colorless crystals; $[\alpha]_D^{30} = +153^{\circ}$ (c = 1.00 in CHCl₃, 96% ee); m.p. 118–119°C; IR (ATR): $\bar{v} = 1758$, 1509, 1248, 1178, 1092, 1063 cm⁻¹; ¹H NMR (CDCl₃): $\delta = 7.69 - 7.65$ (m, 2H), 7.45–7.35 (m, 3H), 7.07 (d, J = 8.6 Hz, 2H), 6.83 (d, J = 8.6 Hz, 2H), 5.91 (d, J = 5.4 Hz, 1H), 3.77 (s, 3H), 3.44 (d, J = 5.4 Hz, 1H), 1.41 (s, 3H), 1.03 ppm (s, 3H); ¹³C NMR (CDCl₃): $\delta = 173.5$, 158.7, 148.7, 132.0, 130.6, 129.5, 128.9, 128.4, 124.4, 113.8, 104.0, 55.2, 49.2, 41.3, 25.9, 21.7 ppm; elemental analysis: calcd for $C_{20}H_{20}O_3$: C 77.90, H 6.54; found: C 77.86, H 6.54; HPLC analysis: DAICEL Chiralcel OD-H, hexane/2-propanol 50:1, $\lambda = 254$ nm, flow rate = 1.0 mL min⁻¹, retention time = 9.5 min (minor) and 11.1 min (major).

5e: Colorless crystals; $[\alpha]_D^{30} = +157^{\circ}$ (c=1.00 in CHCl₃, 95% ee); m.p. 105–107°C; IR (ATR): $\bar{v}=1765$, 1512, 1284, 1246, 1178, 1091, 1065, 1029 cm⁻¹; ¹H NMR (CDCl₃) $\delta=7.61$ (d, J=8.9 Hz, 2H), 7.32–7.22 (m, 3 H), 7.17–7.14 (m, 2 H), 6.90 (d, J=8.9 Hz, 2 H), 5.79 (d, J=5.4 Hz, 1 H), 3.81 (s, 3 H), 3.46 (d, J=5.4 Hz, 1 H), 1.42 (s, 3 H), 1.03 ppm (s, 3 H); ¹³C NMR (CDCl₃) $\delta=173.6$, 160.1, 148.7, 139.0, 128.5, 128.4, 127.3, 125.8, 124.6, 113.8, 101.8, 55.3, 50.0, 41.1, 26.0, 21.7 ppm; elemental analysis: calcd for C₂₀H₂₀O₃: C 77.90, H 6.54; found: C 77.82, H 6.73; HPLC analysis: DAICEL Chiralpak AD-H, hexane/2-propanol 9:1, $\lambda=254$ nm, flow rate = 1.0 mL min⁻¹, retention time = 14.0 min (major) and 15.4 min (minor).

5 f: Colorless crystals; $[\alpha]_D^{30} = +107^{\circ}$ (c=1.00 in CHCl₃, 88% ee); m.p. 115–117°C; IR (ATR): $\bar{\nu}=1754$, 1511, 1251, 1178, 1105, 1073, 1021, 1010 cm⁻¹; 1 H NMR (CDCl₃): $\delta=7.60$ (d, J=8.9 Hz, 2H), 7.42 (d, J=8.4 Hz, 2H), 7.03 (d, J=8.4 Hz, 2H), 6.91 (d, J=8.9 Hz, 2H), 5.74 (d, J=5.4 Hz, 1H), 3.82 (s, 3H), 3.44 (d, J=5.4 Hz, 1H), 1.42 (s, 3H), 1.02 ppm (s, 3H); 13 C NMR (CDCl₃): $\delta=173.2$, 160.2, 149.1, 138.1, 131.5, 130.1, 125.9, 124.3, 121.2, 113.8, 101.1, 55.3, 49.5, 41.0, 25.9, 21.7 ppm; elemental analysis: calcd for $C_{20}H_{19}BrO_3$: C 62.03, H 4.95; found: C 61.73, H 5.14; HPLC analysis: DAICEL Chiralcel OD-H, hexane/2-propanol = 50:1, $\lambda=254$ nm, flow rate = 1.0 mLmin⁻¹, retention time = 14.7 min (major) and 16.1 min (minor).

5g: Colorless oil; $[\alpha]_D^{29} = +109^{\circ}$ (c=1.00 in CHCl₃, 89% ee); IR (ATR): $\nu=1758$, 1511, 1247, 1178, 1094, 1072, 1029, 1005 cm⁻¹; ¹H NMR (CDCl₃): $\delta=7.59-7.48$ (m, 4H), 7.06 (d, J=8.9 Hz, 2H), 6.83 (d, J=8.9 Hz, 2H), 5.92 (d, J=5.4 Hz, 1H), 3.78 (s, 3H), 3.44 (d, J=5.4 Hz, 1H), 1.41 (s, 3H), 1.03 ppm (s, 3H); ¹³C NMR (CDCl₃): $\delta=173.2$, 158.8, 147.8, 131.5, 130.9, 130.3, 129.4, 125.9, 123.0, 113.9, 104.6, 55.2, 49.2, 41.3, 25.9, 21.7 ppm; HRMS (DEI⁺): m/z calcd for C₂₀H₁₉BrO₃ [M]⁺: 386.0518; found: 386.0517; HPLC analysis: DAICEL Chiralcel OD-H, hexane/2-propanol 50:1, $\lambda=254$ nm, flow rate = 1.0 mL min⁻¹, retention time = 12.5 min (major) and 26.1 min (minor).

5h: Colorless oil; $[\alpha]_D^{24} = +64.3^{\circ}$ (c=1.00 in CHCl₃, 95 % ee); IR (ATR): $\bar{v}=1758$, 1448, 1332, 1279, 1240, 1099 cm⁻¹; ¹H NMR (CDCl₃): $\delta=7.64-7.59$ (m, 2H), 7.40–7.32 (m, 3H), 5.67 (d, J=4.6 Hz, 1H), 2.50–2.41 (m, 1H), 1.34 (s, 3H), 1.22 (s, 3H), 1.10 ppm (d, J=7.0 Hz, 3H); ¹³C NMR (CDCl₃): $\delta=174.3$, 147.9, 132.1, 128.6, 128.3, 124.2, 105.8, 40.4, 36.9, 24.3, 20.0, 15.4 ppm; HRMS (DEI⁺): m/z calcd for C₁₄H₁₆O₂ [M]⁺: 216.1150; found: 216.1150; HPLC analysis: DAICEL Chiralcel OD-H, hexane/2-propanol 50:1, $\lambda=254$ nm, flow rate=1.0 mLmin⁻¹, retention time=6.1 min (major) and 6.6 min (minor).

5i: Colorless crystals; $[\alpha]_D^{28} = +138^{\circ}$ (c=1.00 in CHCl₃, 93 % ee); m.p. 38–39 °C; IR (ATR): $\bar{v}=2961$, 1753, 1388, 1350, 1276, 1206, 1105, 1051 cm⁻¹;

¹H NMR (CDCl₃): $\delta=7.67-7.63$ (m, 2H), 7.39–7.34 (m, 3H), 5.73 (d, J=6.5 Hz, 1H), 2.20 (dd, J=6.5, 3.8 Hz, 1H), 2.18–2.03 (m, 1H), 1.35 (s, 3H), 1.34 (s, 3H), 0.98 (d, J=6.8 Hz, 3H), 0.76 ppm (d, J=6.8 Hz, 3H);

¹³C NMR (CDCl₃): $\delta=174.9$, 149.4, 132.3, 128.7, 128.3, 124.4, 99.8, 49.5, 39.3, 28.8, 27.8, 21.6, 21.2, 15.6 ppm; elemental analysis: calcd for C₁₆H₂₀O₂: C 78.65, H 8.25; found: C 78.97, H 8.36; HPLC analysis: DAICEL Chiralcel OD-H, hexane/2-propanol=1000:1, $\lambda=254$ nm, flow rate =1.0 mL min⁻¹, retention time=15.2 min (minor) and 16.2 min (major).

5j: Colorless crystals; $[\alpha]_D^{17} = +27.4^{\circ}$ (c = 0.50 in CHCl₃, 57% ee); m.p. 72–74°C; IR (ATR): $\bar{\nu} = 1759$, 1494, 1449, 1317, 1279, 1141, 1083, 1043 cm⁻¹; 1 H NMR (CDCl₃): $\delta = 7.67-7.63$ (m, 2H), 7.42–7.23 (m, 8H), 5.83 (d, J = 3.0 Hz, 1H), 3.58 (dd, J = 11.1, 3.0 Hz, 1H), 2.79 (dq, J = 11.1, 6.8 Hz, 1H), 1.22 ppm (d, J = 6.8 Hz, 3H); 13 C NMR (CDCl₃): $\delta = 170.9$, 149.4, 141.5, 132.0, 129.0, 128.9, 128.4, 127.6, 127.4, 124.5, 105.0, 44.9, 41.0, 14.1 ppm; elemental analysis: calcd for C₁₈H₁₆O₂: C 81.79, H 6.10; found: C 81.77, H 6.24; HPLC analysis: DAICEL Chiralpak AD-H, hexane/2-propanol = 50:1, $\lambda = 254$ nm, flow rate = 1.0 mL min⁻¹, retention time = 17.1 min (major) and 17.7 min (minor).

5k:^[3e] Colorless oil; $[\alpha]_{19}^{19} = +123^{\circ}$ (c=0.33 in CHCl₃, 84% ee); IR (ATR): $\bar{v}=1759$, 1494, 1450, 1279, 1143, 1073 cm⁻¹; ¹H NMR (CDCl₃): $\delta=7.68-7.64$ (m, 2H), 7.41–7.21 (m, 8H), 5.84 (d, J=4.6 Hz, 1H), 3.71 (dd, J=7.3, 4.6 Hz, 1H), 2.73 (q, J=7.3 Hz, 1H), 1.81–1.64 (m, 2H), 1.04 ppm (t, J=7.3 Hz, 3H); ¹³C NMR (CDCl₃): $\delta=169.8$, 149.3, 141.3, 132.0, 129.0, 128.9, 128.4, 127.3, 127.3, 124.5, 103.5, 48.0, 42.4, 22.8, 11.4 ppm; HPLC analysis: DAICEL Chiralpak AD-H, hexane/2-propanol=50:1, $\lambda=254$ nm, flow rate=1.0 mLmin⁻¹, retention time=16.5 min (major) and 17.7 min (minor).

51: Colorless crystals; $[\alpha]_D^{22} = +158^{\circ}$ (c = 0.50 in CHCl₃, 88 % ee); m.p. 108–109 °C; IR (ATR): $\bar{v} = 2962$, 1760, 1493, 1276, 1235, 1177, 1086, 1070 cm⁻¹; ¹H NMR (CDCl₃): $\delta = 7.70$ –7.66 (m, 2 H), 7.42–7.19 (m, 8 H), 5.86 (d, J = 5.1 Hz, 1 H), 3.61 (t, J = 5.1 Hz, 1 H), 2.89–2.81 (m, 1 H), 1.82–1.72 (m, 2 H), 1.46–1.33 (m, 1 H), 0.90 (d, J = 6.5 Hz, 3 H), 0.86 ppm (d, J = 6.5 Hz, 3 H); ¹³C NMR (CDCl₃): $\delta = 170.1$, 149.5, 141.2, 132.0, 129.0, 128.9, 128.4, 127.3, 127.2, 124.5, 102.5, 44.9, 43.6, 39.6, 26.0, 22.7, 22.0 ppm; elemental analysis: calcd for C₂₁H₂₂O₂: C 82.32, H 7.24; found: C 82.00, H 7.21; HPLC analysis: DAICEL Chiralpak AD-H, hexane/2-propanol 50:1, $\lambda = 254$ nm, flow rate = 1.0 mL min⁻¹, retention time = 12.2 min (major) and 14.3 min (minor).

5m: Colorless crystals; $[\alpha]_D^{21} = +188^{\circ}$ (c=1.00 CHCl₃, 96% ee); m.p. 73–75 °C; IR (ATR): $\tilde{v}=2962$, 1756, 1494, 1450, 1279, 1180, 1123, 1071 cm⁻¹; ¹H NMR (CDCl₃): $\delta=7.70$ –7.66 (m, 2H), 7.42–7.16 (m, 8 H), 5.86 (d, J=5.9 Hz, 1H), 3.81 (dd, J=5.9, 3.2 Hz, 1H), 2.55 (dd, J=7.6, 3.2 Hz, 1H), 2.08–1.96 (m, 1H), 1.15 (d, J=6.8 Hz, 3H), 1.05 ppm (d, J=6.8 Hz, 3H); ¹³C NMR (CDCl₃): $\delta=168.9$, 149.8, 141.3, 132.0, 129.0, 128.9, 128.4, 127.2, 127.0, 124.5, 101.9, 54.3, 41.2, 29.1, 21.1, 20.1 ppm; elemental analysis: calcd for C₂₀H₂₀O₂: C 82.16, H 6.89; found: C 82.25, H 6.98; HPLC analysis: Data Calculus Ca

5n: Colorless crystals; $[\alpha]_D^{22} = +250^{\circ}$ (c = 0.50 in CHCl₃, 96 % ee); m.p. 90–92 °C; IR (ATR): $\bar{v} = 2962$, 1758, 1745, 1494, 1221, 1195, 1068, 1095 cm⁻¹; ¹H NMR (CDCl₃): $\delta = 7.70$ –7.65 (m, 2 H), 7.41–7.15 (m, 8 H), 5.87 (d, J = 6.5 Hz, 1 H), 3.88 (d, J = 6.5 Hz, 1 H), 2.60 (s, 1 H), 1.13 ppm (s, 9 H); ¹³C NMR (CDCl₃): $\delta = 168.1$, 149.9, 142.5, 132.1, 129.0, 129.0, 128.4, 127.1, 126.8, 124.5, 101.9, 57.8, 39.5, 34.8, 28.6 ppm; elemental analysis: calcd for $C_{21}H_{22}O_2$: C 82.32, H 7.24; found: C 82.20, H 7.20; HPLC analysis: DAICEL Chiralpak AD-H, hexane/2-propanol 50:1, $\lambda = 254$ nm, flow rate = 1.0 mL min⁻¹, retention time = 14.0 min (major) and 20.2 min (minor).

50: Colorless oil; $[\alpha]_{\rm D}^{14} = +141^{\circ}$ (c=0.33 in CHCl₃, 95% ee); IR (ATR): $\bar{v}=1758$, 1507, 1224, 1177, 1071 cm⁻¹; 1 H NMR (CDCl₃): $\delta=7.76-7.66$ (m, 2 H), 7.47–7.35 (m, 3 H), 7.20–7.09 (m, 2 H), 7.03–6.95 (m, 2 H), 5.85 (d, J=5.9 Hz, 1 H), 3.81 (dd, J=5.9, 3.0 Hz, 1 H), 2.55–2.46 (m, 1 H), 2.08–1.94 (m, 1 H), 1.14 (d, J=6.8 Hz, 3 H), 1.05 ppm (d, J=6.8 Hz, 3 H); 13 C NMR (CDCl₃): $\delta=168.7$, 161.8 (d, J=246.2 Hz), 150.0, 137.0 (d, J=3.4 Hz), 131.8, 129.1, 128.6 (d, J=7.8 Hz), 128.4, 124.5, 115.8 (d, J=21.3 Hz), 101.5, 54.6, 40.4, 29.0, 21.1, 20.2 ppm; HRMS (DEI+): m/z calcd for C₂₀H₁₉FO₂ [M]+: 310.1369; found: 310.1370; HPLC analysis: DAICEL Chiralpak AD-H, hexane/2-propanol 50:1, $\lambda=254$ nm, flow rate = 1.0 mL min⁻¹, retention time = 16.3 min (major) and 18.1 min (minor).

5p: Colorless oil; $[\alpha]_{\rm D}^{1.6} = +170^{\circ} \ (c=0.33 \ {\rm in \ CHCl_3}, \ 94\% \ ee)$; IR (ATR): $\bar{v}=1760,\ 1508,\ 1232,\ 1159,\ 1067\ {\rm cm^{-1}};\ ^1{\rm H}\ {\rm NMR}\ ({\rm CDCl_3})$: $\delta=7.68-7.62$ (m, 2H), 7.41–7.16 (m, 5H), 7.11–7.02 (m, 2H), 5.79 (d, $J=5.9\ {\rm Hz},\ 1{\rm H})$, 3.85–3.78 (m, 1H), 2.60–2.53 (m, 1H), 2.08–1.94 (m, 1H), 1.15 (d, $J=6.8\ {\rm Hz},\ 3{\rm H})$, 1.05 ppm (d, $J=6.8\ {\rm Hz},\ 3{\rm H})$; $^{13}{\rm C}\ {\rm NMR}\ ({\rm CDCl_3})$: $\delta=168.7$,

163.0 (d, J=248.9 Hz), 149.0, 141.3, 129.0, 128.2 (d, J=3.3 Hz), 127.3, 127.0, 126.4 (d, J=7.9 Hz), 115.4 (d, J=21.8 Hz), 101.6, 54.2, 41.2, 29.1, 21.1, 20.1 ppm; HRMS (DEI⁺): m/z calcd for $C_{20}H_{19}FO_2$ [M]⁺: 310.1369; found: 310.1373; HPLC analysis: DAICEL Chiralcel OD-H, hexane/2-propanol=50:1, λ =254 nm, flow rate=1.0 mLmin⁻¹, retention time=8.8 min (major) and 12.2 min (minor).

5q: Colorless oil; $[\alpha]_D^{17} = +160^{\circ}$ (c = 0.50 in CHCl₃, 94 % ee); IR (ATR): $\bar{v} = 1758$, 1510, 1248, 1176, 1071, 1033, 1018 cm⁻¹; ¹H NMR (CDCl₃): $\delta = 7.69 - 7.65$ (m, 2H), 7.44–7.36 (m, 3H), 7.11 (d, J = 8.6 Hz, 2H), 6.84 (d, J = 8.6 Hz, 2H), 5.85 (d, J = 5.9 Hz, 1H), 3.79–3.73 (m, 4H), 2.51 (dd, J = 7.8, 3.2 Hz, 1H), 2.08–1.96 (m, 1H), 1.14 (d, J = 6.8 Hz, 3H), 1.04 ppm (d, J = 6.8 Hz, 3H); ¹³C NMR (CDCl₃): $\delta = 169.0$, 158.6, 149.6, 133.3, 132.0, 128.9, 128.4, 128.1, 124.4, 114.3, 102.2, 55.3, 54.6, 40.3, 28.9, 21.1, 20.2 ppm; HRMS (DEI⁺): m/z calcd for C₂₁H₂₂O₃ [M]⁺: 322.1569; found: 322.1567; HPLC analysis: DAICEL Chiralcel OD-H, hexane/2-propanol 50:1, $\lambda = 254$ nm, flow rate = 1.0 mL min⁻¹, retention time = 10.6 min (minor) and 11.8 min (major).

5r: Colorless oil; $[\alpha]_D^{19} = +142^{\circ}$ (c=1.00 in CHCl₃, 97% ee); IR (ATR): $\bar{v}=1757$, 1608, 1511, 1250, 1172, 1067, 1023 cm⁻¹, ¹H NMR (CDCl₃): $\delta=7.61$ (d, J=8.6 Hz, 2H), 7.41–7.12 (m, 5 H), 6.91 (d, J=8.6 Hz, 2H), 5.71 (d, J=5.7 Hz, 1H), 3.88–3.80 (m, 4H), 2.55–2.50 (m, 1H), 2.07–1.96 (m, 1H), 1.14 (d, J=6.8 Hz, 3H), 1.04 ppm (d, J=6.8 Hz, 3H); ¹³C NMR (CDCl₃): $\delta=169.1$, 160.1, 149.6, 141.6, 128.9, 127.1, 127.0, 125.9, 124.6, 113.8, 99.9, 55.3, 54.4, 41.1, 29.0, 21.1, 20.1 ppm; HRMS (DEI⁺): m/z calcd for C₂₁H₂₂O₃ [M]⁺: 322.1569; found: 322.1564; HPLC analysis: DAICEL Chiralcel OD-H, hexane/2-propanol 50:1, $\lambda=254$ nm, flow rate =1.0 mL min⁻¹, retention time =13.7 min (major) and 18.1 min (minor).

5 s:^[14] Colorless crystals; $[\alpha]_D^{19} = +110^{\circ}$ (c=1.00 in CHCl₃, 95 % ee); m.p. 135–136 °C; IR (ATR): $\bar{v}=1757$, 1608, 1511, 1250, 1172, 1070, 1009 cm⁻¹; ¹H NMR (CDCl₃): $\delta=7.61$ (d, J=8.9 Hz, 2H), 7.42 (d, J=8.4 Hz, 2H), 7.07 (d, J=8.6 Hz, 2H), 6.91 (d, J=8.9 Hz, 2H), 5.68 (d, J=5.7 Hz, 1H), 3.82 (s, 3H), 3.80–3.71 (m, 1H), 2.51–2.44 (m, 1H), 2.07–1.94 (m, 1H), 1.14 (d, J=6.8 Hz, 3H), 1.04 ppm (d, J=6.8 Hz, 3H); ¹³C NMR (CDCl₃): $\delta=168.7$, 160.2, 150.0, 140.6, 132.0, 128.8, 126.0, 124.3, 121.0, 113.8, 99.1, 55.3, 54.4, 40.5, 29.0, 21.1, 20.2 ppm; elemental analysis: calcd for C₂₁H₂₁BrO₃: C 62.85, H 5.27; found: C 62.83, H 5.34; HPLC analysis: DAICEL Chiralpak AD-H, hexane/2-propanol 50:1, $\lambda=254$ nm, flow rate = 1.0 mL min⁻¹, retention time = 42.4 min (3*S*,4*R*) and 47.7 min (3*R*,4*S*).

5t: Colorless oil; $[\alpha]_D^{20} = +104^{\circ}$ (c=0.50 in CHCl₃, 92% ee); IR (ATR): $\tilde{v}=1761$, 1510, 1248, 1175, 1069, 1028, 1006 cm⁻¹; ¹H NMR (CDCl₃): $\delta=7.59-7.48$ (m, 4H), 7.11 (d, J=8.6 Hz, 2H), 6.84 (d, J=8.6 Hz, 2H), 5.85 (d, J=5.7 Hz, 1H), 3.81–3.70 (m, 4H), 2.56–2.49 (m, 1H), 2.06–1.91 (m, 1H), 1.13 (d, J=6.8 Hz, 3H), 1.04 ppm (d, J=6.8 Hz, 3H); ¹³C NMR (CDCl₃): $\delta=168.7$, 158.7, 148.7, 133.0, 131.5, 130.9, 128.0, 126.0, 123.1, 114.3, 102.9, 55.3, 54.4, 40.4, 29.0, 21.1, 20.1 ppm; HRMS (DEI⁺): mlz calcd for C₂₁H₂₁BrO₃ [M]⁺: 400.0674; found: 400.0674; HPLC analysis: DAICEL Chiralcel OD-H, hexane/2-propanol 50:1, $\lambda=254$ nm, flow rate =1.0 mL min⁻¹, retention time=11.5 min (major) and 14.1 min (minor)

5u: Colorless oil; $[\alpha]_{\rm D}^{12}=+119^{\circ}\ (c=0.67\ \text{in CHCl}_3,\,85\%\ ee)$; IR (ATR): $\bar{v}=1758,\,1511,\,1248,\,1177,\,1143,\,1076,\,1031\ \text{cm}^{-1};\,^{1}\text{H NMR (CDCl}_3)$: $\delta=7.67-7.63\ (m,\,2\text{H}),\,7.43-7.33\ (m,\,3\text{H}),\,7.14\ (d,\,J=8.6\ \text{Hz},\,2\text{H}),\,6.87\ (d,\,J=8.6\ \text{Hz},\,2\text{H}),\,5.82\ (d,\,J=4.9\ \text{Hz},\,1\text{H}),\,3.78\ (s,\,3\text{H}),\,3.66\ (dd,\,J=7.3,\,4.9\ \text{Hz},\,1\text{H}),\,2.70\ (q,\,J=7.3\ \text{Hz},\,1\text{H}),\,1.78-1.65\ (m,\,2\text{H}),\,1.03\ \text{ppm}\ (t,\,J=7.3\ \text{Hz},\,3\text{H});\,^{13}\text{C NMR (CDCl}_3)$: $\delta=169.9,\,158.6,\,149.0,\,133.3,\,132.0,\,128.9,\,128.4,\,128.3,\,124.4,\,114.3,\,103.8,\,55.3,\,48.2,\,41.6,\,22.7,\,11.4\ \text{ppm}$; HRMS (DEI⁺): m/z calcd for $C_{20}H_{20}O_3\ [M]^+$: 308.1412; found: 308.1411; HPLC analysis: DAICEL Chiralcel OD-H, hexane/2-propanol = $50:1,\,\lambda=254\ \text{nm}$, flow rate = $1.0\ \text{mLmin}^{-1}$, retention time = $16.2\ \text{min}\ (\text{minor})$ and $18.6\ \text{min}\ (\text{major})$.

5v: Colorless oil; $[\alpha]_{\rm D}^{14}$ + +97.3° (c=0.50 in CHCl₃, 87% ee); IR (ATR): \bar{v} =1761, 1608, 1511, 1249, 1174, 1144, 1073, 1026 cm⁻¹; 1 H NMR (CDCl₃): δ =7.59 (d, J=8.6 Hz, 2H), 7.36–7.20 (m, 5H), 6.89 (d, J=8.6 Hz, 2H), 5.69 (d, J=4.3 Hz, 1H), 3.81 (s, 3H), 3.68 (dd, J=7.3, 4.3 Hz, 1H), 2.71 (q, J=7.3 Hz, 1H), 1.79–1.65 (m, 2H), 1.03 ppm (t, J=7.3 Hz, 3H); 13 C NMR (CDCl₃): δ =169.9, 160.1, 149.0, 141.6, 128.8,

127.2, 127.2, 125.9, 124.5, 113.7, 101.6, 55.3, 48.0, 42.3, 22.7, 11.4 ppm; HRMS (DEI⁺): m/z calcd for $C_{20}H_{20}O_3$ [M]⁺: 308.1412; found 308.1415; HPLC analysis: DAICEL Chiralcel OD-H, hexane/2-propanol 50:1, λ = 254 nm, flow rate = 1.0 mLmin⁻¹, retention time = 18.7 min (major) and 24.5 min (minor).

5w: Colorless crystals; $[\alpha]_D^{17} = +155^{\circ}$ (c = 0.50 in CHCl₃, 86% ee); m.p. 96–97 °C; IR (ATR): $\bar{v} = 1760$, 1450, 1145, 1071 cm⁻¹; ¹H NMR (CDCl₃): $\delta = 7.45-7.17$ (m, 10 H), 7.09 (d, J = 15.9 Hz, 1 H), 6.50 (d, J = 15.9 Hz, 1 H), 5.37 (d, J = 4.6 Hz, 1 H), 3.66 (dd, J = 7.0, 4.6 Hz, 1 H), 2.70 (q, J = 7.0 Hz, 1 H), 1.80–1.64 (m, 2 H), 1.03 ppm (t, J = 7.3 Hz, 3 H); ¹³C NMR (CDCl₃): $\delta = 169.5$, 148.7, 141.3, 136.0, 129.8, 128.9, 128.6, 128.1, 127.3, 127.2, 126.7, 119.6, 108.2, 48.1, 42.6, 22.8, 11.4 ppm; elemental analysis: calcd for C₂₁H₂₀O₂: C 82.86, H 6.62; found: C 82.69, H 6.70; HPLC analysis: DAICEL Chiralcel OD-H, hexane/2-propanol 50:1, $\lambda = 254$ nm, flow rate = 1.0 mL min⁻¹, retention time = 32.2 min (minor) and 38.5 min (major).

9: Pd/C (10%; 40.0 mg) was added to a solution of (+)-5a (400 mg, 1.44 mmol, 90% *ee*) in EtOH/THF (5:1; 12 mL), and the mixture was stirred under hydrogen at ambient temperature for 1 h. The reaction mixture was then filtered through a Celite pad, and the filtrate was concentrated under reduced pressure to give carboxylic acid 9 (390 mg, 96% yield) as a colorless oil. [α]_D²⁰ = +23.0° (c = 1.00 in CHCl₃); IR (ATR): \bar{v} = 3027, 2977, 2942, 1693, 1453, 1287 cm⁻¹; ¹H NMR (CDCl₃): δ = 7.36–7.12 (m, 8H), 7.08–7.04 (m, 2H), 3.02 (dd, J = 11.9, 2.7 Hz, 1H), 2.49–2.25 (m, 2H), 2.23–2.07 (m, 1H), 1.98–1.86 (m, 1H), 1.15 (s, 3H), 1.04 ppm (s, 3H); ¹³C NMR (CDCl₃): δ = 1844, 141.9, 139.4, 129.8, 128.2, 128.2, 127.9, 126.8, 125.7, 52.1, 46.6, 34.2, 32.1, 24.8, 20.4 ppm; HRMS (FAB⁺): m/z calcd for C₁₀H₂₂O₂Li [M+Li]⁺: 289.1780; found: 289.1779.

10:[11] A solution of oxalyl chloride (113 mg, 0.80 mmol) in CH₂Cl₂ (2 mL) was added to a stirred solution of 9 (113 mg, 0.40 mmol) in CH₂Cl₂ (10 mL). The mixture was heated at reflux for 1 h, and the solvent and oxalyl chloride were removed under reduced pressure. CH2Cl2 (10 mL), 4-bromoaniline (68.8 mg, 0.40 mmol), and a solution of triethylamine (80.9 mg, 0.80 mmol) in CH₂Cl₂ (2 mL) were added successively to the residue at room temperature. The mixture was stirred for 1 h at the same temperature, quenched with aqueous HCl (1 M), and extracted with EtOAc. The organic layer was washed with saturated aqueous NaHCO₃ and brine, dried over anhydrous Na2SO4, and evaporated. The crude product was purified by PTLC and recrystallized from EtOAc/hexane to afford the corresponding carboxamide 10 (119 mg, 68% yield) as colorless crystals. $[\alpha]_D^{18} = +26.4^{\circ} (c = 0.73 \text{ in CHCl}_3, >99\% ee); \text{ m.p. } 153-$ 154°C; IR (ATR): \tilde{v} =3410, 3026, 2951, 1653, 1587, 1511, 1487, 1453, 1390, 1304, 1241 cm⁻¹; ¹H NMR (CDCl₃): $\delta = 7.42 - 7.12$ (m, 12 H), 7.05– 6.99 (m, 2H), 6.95 (br s, 1H), 2.96 (dd, J=11.9, 3.0 Hz, 1H), 2.51–2.37 (m, 1H), 2.34–1.92 (m, 3H), 1.24 (s, 3H), 1.13 ppm (s, 3H); ¹³C NMR (CDCl₃): $\delta = 175.2$, 141.8, 139.5, 136.5, 131.6, 129.7, 128.3, 128.2, 128.0, 126.9, 125.7, 121.7, 116.7, 52.9, 47.1, 34.1, 31.4, 24.6, 21.8 ppm; elemental analysis: calcd for C₂₅H₂₆BrNO: C 68.81, H 6.01, N 3.21; found: C 69.04, H 6.07, N 3.18; HPLC analysis: DAICEL Chiralpak AD-H, hexane/2propanol 4:1, $\lambda = 254 \text{ nm}$, flow rate = 1.0 mL min⁻¹, retention time = 7.2 min (3S) and 19.1 min (3R).

Acknowledgements

This study was supported in part by a Grant of the 21st Century COE Program from the Ministry of Education, Culture, Sports, Science, and Technology (MEXT), Japan. The authors thank Mr. Nobuhiro Marubayashi (Mitsubishi Pharma Corporation) for his support in X-ray crystallographic analysis.

 a) K. A. Jørgensen, Angew. Chem. 2000, 112, 3702-3733; Angew. Chem. Int. Ed. 2000, 39, 3558-3588; b) X. Zhang, H. Du, Z. Wang,

- Y-D. Wu, K. Ding, *J. Org. Chem.* **2006**, *71*, 2862–2869 and references cited therein.
- [2] a) D. Rosenthal, P. Grabowich, E. F. Sabo, J. Fried, J. Am. Chem. Soc. 1963, 85, 3971–3979; b) T. Kume, H. Iwasaki, Y. Yamamoto, K. Akiba, Tetrahedron Lett. 1988, 29, 3825–3828; c) A. K. Mandal, D. G. Jawalker, Tetrahedron Lett. 1986, 27, 99–100; d) A. K. Mandal, D. G. Jawalker, J. Org. Chem. 1989, 54, 2364–2369; e) S. H. Thang, D. J. Rigg, Synth. Commun. 1993, 23, 2355–2361; f) J. R. Heys, S. G. Senderoff, J. Org. Chem. 1989, 54, 4702–4706; g) D. C. Harrowven, J. C. Hannam, Tetrahedron 1999, 55, 9333–9340; h) J. A. Robl, Tetrahedron Lett. 1990, 31, 3421–3424; i) Y. D. Gong, H. Tanaka, N. Iwasawa, K. Narasaka, Bull. Chem. Soc. Jpn. 1998, 71, 2181–2185; j) F.-Y. Zhang, E. J. Corey, Org. Lett. 2000, 2, 1097–1100.
- [3] a) D. A. Oare, C. H. Heathcock, J. Org. Chem. 1990, 55, 157–172;
 b) S. Kobayashi, M. Moriwaki, Synlett 1997, 5, 551–552;
 c) A. R. Katritzky, O. V. Denisko, J. Org. Chem. 2002, 67, 3104–3108.
- [4] a) T. Tozawa, H. Fujisawa, T. Mukaiyama, *Chem. Lett.* **2004**, *33*, 1454–1455; b) T. Tozawa, Y. Yamane, T. Mukaiyama, *Chem. Lett.* **2005**, *34*, 514–515.
- [5] For recent reviews, see: a) M. J. O'Donnell, Acc. Chem. Res. 2004, 37, 506-517; b) B. Lygo, B. I. Andrews, Acc. Chem. Res. 2004, 37, 518-525; c) T. Ooi, K. Maruoka, Acc. Chem. Res. 2004, 37, 526-533; d) K. Maruoka and T. Ooi, Chem. Rev. 2003, 103, 3013-3028.
- [6] For the preparation and X-ray crystallographic analysis of quaternary ammonium p-nitrophenoxide, see: E. J. Corey, F. Xu, M. C. Noe, J. Am. Chem. Soc. 1997, 119, 12414–12415.
- [7] A. Ando, T. Miura, T. Tatematsu, T. Shioiri, *Tetrahedron Lett.* 1993, 34, 1507–1510.
- [8] a) R. Goddard, H. M. Herzog, M. T. Reetz, *Tetrahedron* 2002, 58, 7847–7850; b) A. W. Hanson, A. W. McCulloch, A. G. McInnes, *Tetrahedron Lett.* 1982, 23, 607–610.
- [9] T. Tozawa, Y. Yamane, T. Mukaiyama, Chem. Lett. 2006, 35, 56-57.
- [10] B. Lygo, P. G. Wainwright, Tetrahedron Lett. 1997, 38, 8595-8598.
- [11] CCDC-612957 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge at www.ccdc.cam.ac.uk/conts/retrieving.html (or from the Cambrige Crystallographic Data Centre, 12 Union Road, Cambrige CB21EZ, UK; fax: (+44) 1223–336–033; or deposit@ccdc.cam.ac.uk).
- [12] For some recent reports of hydrogen-bond-promoted asymmetric catalysis, see: a) S. Rajaram, M. S. Sigman, Org. Lett. 2005, 7, 5473–5475; b) T. Ooi, D. Ohara, K. Fukumoto, K. Maruoka, Org. Lett. 2005, 7, 3195–3197; c) A. K. Unni, N. Takenaka, H. Yamamoto, V. H. Rawal, J. Am. Chem. Soc. 2005, 127, 1336–1337; d) T. Ooi, D. Ohara, M. Tamura, K. Maruoka, J. Am. Chem. Soc. 2004, 126, 6844–6845; e) Y. Huang, A. K. Unni, A. N. Thadani, V. H. Rawal, Nature 2003, 424, 146; see also reference [1b].
- [13] T. Tozawa, Y. Yamane, T. Mukaiyama, Chem. Lett. 2006, 35, 360–361.
- [14] CCDC-612956 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge at www.ccdc.cam.ac.uk/conts/retrieving.html (or from the Cambrige Crystallographic Data Centre, 12 Union Road, Cambrige CB21EZ, UK; fax: (+44) 1223–336–033; or deposit@ccdc.cam.ac.uk).
- [15] J. M. Chong, L. Shen, N. J. Taylor, J. Am. Chem. Soc. 2000, 122, 1822–1823.
- [16] S. Kobayashi, K. Manabe, H. Ishitani, J. Matsuo in Science of Synthesis: Houben-Weyl Methods of Molecular Transformations, Vol. 4 (Eds.: D. Bellus, S. V. Ley, R. Noyori, M. Regitz, E. Schaumann, I. Shinkai, E. J. Thomas, B. M. Trost), Thieme, Stuttgart, 2002, pp. 317–369.
- [17] N-(9-Anthracenylmethyl)-O-[3,5-bis(trifluoromethyl)benzyl]cinchonidinium bromide was prepared according to the procedure reported by Corey et al.^[6]

Received: July 20, 2006 Revised: October 10, 2006 Published online: December 12, 2006